0001144204-18-028483.txt : 20180515 0001144204-18-028483.hdr.sgml : 20180515 20180515100119 ACCESSION NUMBER: 0001144204-18-028483 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180515 DATE AS OF CHANGE: 20180515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CASI Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0000895051 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 581959440 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-20713 FILM NUMBER: 18833770 BUSINESS ADDRESS: STREET 1: 9620 MEDICAL CENTER DR STREET 2: STE 300 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 240-864-2600 MAIL ADDRESS: STREET 1: 9620 MEDICAL CENTER DR STREET 2: STE 300 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: ENTREMED INC DATE OF NAME CHANGE: 19960415 10-Q 1 tv493209_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2018

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to _____________.

Commission file number 0-20713

CASI PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		58-1959440
(State or other jurisdiction of		(I.R.S. Employer Identification No.)
incorporation or organization)

9620 Medical Center Drive, Suite 300

Rockville, Maryland

(Address of principal executive offices)

20850

(Zip code)

(240) 864-2600

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES x NO ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES x NO ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨

Accelerated filer ¨

Non-accelerated filer ¨

Smaller reporting company þ

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES ¨ NO x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the most recent practicable date.

Class		Outstanding at May 8, 2018
Common Stock $.01 Par Value		86,145,298

CASI PHARMACEUTICALS, INC.

Table of Contents

		PAGE

PART I. FINANCIAL INFORMATION

Item 1 — Consolidated Financial Statements

Condensed Consolidated Balance Sheets as of March 31, 2018 (unaudited) and December 31, 2017		4

Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2018 and 2017 (unaudited)		5

Condensed Consolidated Statement of Stockholders’ Equity for the Three Months Ended March 31, 2018 (unaudited)		6

Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2018 and 2017 (unaudited)		7

Notes to Condensed Consolidated Financial Statements (unaudited)		8

Item 2 —	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16

Item 3 —	Quantitative and Qualitative Disclosures About Market Risk	24

Item 4 —	Controls and Procedures	24

Part II. OTHER INFORMATION

Item 1 —	Legal Proceedings	24

Item 1A —	Risk Factors	25

Item 2 —	Unregistered Sales of Equity Securities and Use of Proceeds	25

Item 3 —	Defaults Upon Senior Securities	25

Item 4 —	Removed and Reserved	25

Item 5 —	Other Information	25

Item 6 —	Exhibits	25

EXHIBIT INDEX		26

SIGNATURES		27

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements also may be included in other statements that we make. All statements that are not descriptions of historical facts are forward-looking statements. These statements can generally be identified by the use of forward-looking terminology such as “believes,” “expects,” “intends,” “may,” “will,” “should,” or “anticipates” or similar terminology. These forward-looking statements include, among others, statements regarding the timing of our clinical trials, our cash position and future expenses, and our future revenues.

Our forward-looking statements are based on information available to us today, and we will not update these statements. Actual results could differ materially from those currently anticipated due to a number of factors, including: risks relating to interests of our largest stockholders that differ from our other stockholders; the difficulty of executing our business strategy in China; the risk that we will not be able to effectively select, register and commercialize products from our recently acquired portfolio of abbreviated new drug applications (ANDAs); our lack of experience in manufacturing products and uncertainty about our resources and capabilities to do so on a clinical or commercial scale; risks relating to the commercialization, if any, of our products and proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); our inability to predict when or if our product candidates will be approved for marketing by the China Food and Drug Administration authorities; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; the volatility in the market price of our common stock; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; risks associated with our product candidates; risks associated with any early-stage products under development; risk that results in preclinical and early clinical models are not necessarily indicative of later clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; and our dependence on third parties. Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission (“SEC”), which are available at www.sec.gov.

PART I. FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

CASI Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

	March 31, 2018			December 31, 2017
	(Unaudited)			(Note 1)
ASSETS
Current assets:
Cash and cash equivalents	$	49,887,600		$	43,489,935
Investments, at market		1,322,025			-
Prepaid expenses and other		876,026			322,493
Total current assets		52,085,651			43,812,428

Property and equipment, net		1,200,830			1,046,514
Other assets		70,694			242,023
Intangible assets, net		17,804,844			-
Total assets	$	71,162,019		$	45,100,965

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	1,581,931		$	2,087,770
Payable to related parties		-			2,228,366
Accrued liabilities		462,136			745,961
Total current liabilities		2,044,067			5,062,097

Note payable, net of discount		1,498,931			1,498,754
Total liabilities		3,542,998			6,560,851

Commitments and contingencies

Stockholders' equity:
Preferred stock, $1.00 par value: 5,000,000 shares authorized and 0 shares issued and outstanding at March 31, 2018 and December 31, 2017		-			-
Common stock, $.01 par value: 170,0000,000 shares authorized at March 31, 2018 and December 31, 2017; 79,721,421 shares and 69,901,625 shares issued at March 31, 2018 and December 31, 2017, respectively		797,214			699,015
Additional paid-in capital		529,389,427			498,577,372
Treasury stock, at cost: 79,545 shares held at March 31, 2018 and December 31, 2017		(8,034,244	)		(8,034,244	)
Accumulated other comprehensive income		527,251			-
Accumulated deficit		(455,060,627	)		(452,702,029	)
Total stockholders' equity		67,619,021			38,540,114
Total liabilities and stockholders' equity	$	71,162,019		$	45,100,965

See accompanying condensed notes.

CASI Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

	Three Months Ended
	March 31, 2018			March 31, 2017
Revenues:
Product sales	$	-		$	-

Costs and expenses
Research and development		1,697,232			1,049,287
General and administrative		1,303,122			644,163
Acquired in-process research and development		686,998			-
		3,687,352			1,693,450

Interest income, net		(6,729	)		(142	)
Other income		(89,713	)		-
Changes in fair value of contingent rights		-			6,874
Net loss	$	(3,590,910	)	$	(1,700,182	)

Net loss per share (basic and diluted)	$	(0.05	)	$	(0.03	)
Weight average number of shares outstanding (basic and diluted)		71,215,000			60,196,574

Comprehensive loss:
Net loss	$	(3,590,910	)	$	(1,700,182	)
Foreign currency translation adjustment		527,251			-
Total comprehensive loss	$	(3,063,659	)	$	(1,700,182	)

See accompanying condensed notes.

CASI Pharmaceuticals, Inc.

Condensed Consolidated Statement of Stockholders’ Equity

(Unaudited)

															Accumulated
												Additional			Other
	Preferred Stock				Common Stock				Treasury			Paid-in			Comprehensive		Accumulated
	Shares		Amount		Shares		Amount		Stock			Capital			Income		Deficit			Total
Balance at December 31, 2017		-	$	-		69,822,080	$	699,015	$	(8,034,244	)	$	498,577,372		$	-	$	(452,702,029	)	$	38,540,114
Cumulative effect adjustment due to the adoption of ASU 2016-01		-		-		-		-		-			-			-		1,232,312			1,232,312
Issuance of common stock and warrants pursuant to financing agreements		-		-		9,186,452		91,865		-			29,698,352			-		-			29,790,217
Issuance of common stock for options exercised		-		-		57,214		572		-			97,450			-		-			98,022
Issuance of common stock from exercise of warrants		-		-		576,130		5,762		-			967,898			-		-			973,660
Stock issuance costs		-		-		-		-		-			(211,685	)		-		-			(211,685	)
Stock-based compensation expense		-		-		-		-		-			260,040			-		-			260,040
Foreign currency translation adjustment		-		-		-		-		-			-			527,251		-			527,251
Net loss		-		-		-		-		-			-			-		(3,590,910	)		(3,590,910	)
Balance at March 31, 2018		-	$	-		79,641,876	$	797,214	$	(8,034,244	)	$	529,389,427		$	527,251	$	(455,060,627	)	$	67,619,021

See accompanying condensed notes.

CASI Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Three Months Ended
	March 31, 2018			March 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(3,590,910	)	$	(1,700,182	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		65,822			18,528
Amortization of intangible assets		250,141			-
Stock-based compensation expense		260,040			156,250
Acquired in-process research and development		686,998			-
Unrealized gain on equity investment		(89,713	)		-
Non-cash interest		177			1,869
Change in fair value of contingent rights		-			6,874
Changes in operating assets and liabilities:
Prepaid expenses and other		52,886			(17,932	)
Accounts payable		(522,274	)		55,371
Payable to related party		(2,228,366	)		-
Accrued liabilities		(287,672	)		(51,245	)
Net cash used in operating activities		(5,402,871	)		(1,530,467	)

CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment		(155,144	)		(33,509	)
Acquisition of Abbreviated New Drug Applications and related items		(19,171,956	)		-
Net cash used in investing activities		(19,327,100	)		(33,509	)

CASH FLOWS FROM FINANCING ACTIVITIES
Stock issuance costs		(211,685	)		-
Proceeds from sale of common stock and warrants		29,790,217			-
Proceeds from exercise of stock options		98,022			-
Proceeds from exercise of stock warrants		973,660			-
Net cash provided by financing activities		30,650,214			-

Effect of exchange rate changes on cash and cash equivalents		477,422			-
Net increase (decrease) in cash and cash equivalents		6,397,665			(1,563,976	)
Cash and cash equivalents at beginning of period		43,489,935			27,092,928
Cash and cash equivalents at end of period	$	49,887,600		$	25,528,952

See accompanying condensed notes.

CASI Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

March 31, 2018 (unaudited)

Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of CASI Pharmaceuticals, Inc. and its subsidiaries (“CASI” or “the Company”), Miikana Therapeutics, Inc. (“Miikana”) and CASI Pharmaceuticals (Beijing) Co., Ltd. (“CASI China”). The Company previously operated under a different name prior to restructuring its business in 2012 in connection with an investment led by one of the Company’s largest stockholders. CASI China is a non-stock Chinese entity with 100% of its interest owned by CASI. CASI China received approval for a business license from the Beijing Industry and Commercial Administration in August 2012 and has operating facilities in Beijing. All inter-company balances and transactions have been eliminated in consolidation.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, such condensed consolidated financial statements do not include all of the information and disclosures required by U.S. generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. The accompanying December 31, 2017 financial information was derived from the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. Operating results for the three month period ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018 or any other future period. For further information, refer to the Company’s audited consolidated financial statements and footnotes thereto included in its Form 10-K for the year ended December 31, 2017.

Liquidity Risks and Management’s Plans

Since inception, the Company has incurred significant losses from operations and has incurred an accumulated deficit of $455.1 million. The Company restructured its business in 2012 in connection with an investment led by one of the Company’s largest stockholders, followed by implementation of a name change to reflect its core mission and business strategy. The Company expects to continue to incur operating losses for the foreseeable future due to, among other factors, its continuing clinical activities. In March 2018, the Company entered into securities purchase agreements pursuant to which the Company issued 15,432,091 shares of its common stock with accompanying warrants to purchase 6,172,832 shares of its common stock in a $50 million private placement (the “2018 Financing”). The Company received gross proceeds of $29.3 million in March 2018 and received additional gross proceeds of $20.7 million in April 2018. The 2018 Financing closing included an investment from ETP Global Fund, L.P., a healthcare investment fund. The managing member of Emerging Technology Partners, LLC, which is the general partner of ETP Global Fund, L.P., is also the Executive Chairman of the Company. The 2018 Financing also included an investment from IDG-Accel China Growth Fund III L.P. (“IDG-Accel Growth”) and IDG-Accel China III Investors L.P. (“IDG-Accel Investors”). A director and shareholder of IDG-Accel China Growth Fund GP III Associates Ltd., which is the ultimate general partner of IDG-Accel Growth and IDG-Accel Investors, is also a member of the Company’s Board of Directors. In October 2017, the Company entered into securities purchase agreements for an approximately $23.8 million strategic financing. The Company held its initial closing on October 17, 2017, a second closing on October 23, 2017 and a final closing on November 20, 2017 and received approximately $23.4 million in net proceeds, (collectively, the “2017 Closings”). Net proceeds from the 2018 Financing and the 2017 Closings are being used to prepare for the anticipated launch of the Company’s first commercial product in China, to support the Company’s business development activities, to advance the development of the Company’s pipeline, to support its marketing and commercial planning activities, and for other general corporate purposes.

As a result of the 2018 Financing and 2017 Closings, the Company believes that it has sufficient resources to fund its operations at least through May 15, 2019. As of March 31, 2018, approximately $20.9 million of the Company’s cash balance was held by CASI China. The Company intends to continue to exercise tight controls over operating expenditures and will continue to pursue opportunities, as required, to raise additional capital and will also actively pursue non- or less-dilutive capital raising arrangements in China to support the Company’s dual-country approach to drug development.

Acquisition of Abbreviated New Drug Applications

On January 26, 2018, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Sandoz, Inc. (“Sandoz”). Pursuant to the Asset Purchase Agreement, the Company acquired a portfolio of 29 abbreviated new drug applications (“ANDAs”), including 25 ANDAs approved by the U.S. Food and Drug Administration (“FDA”) and four pipeline ANDAs that are pending FDA approval, limited quantities of certain active pharmaceutical ingredient (“API”), and certain manufacturing and other information related to the products (collectively, the ANDAs, API and other information is referred to as the “Acquired Assets”). To facilitate the sale and transition, the parties also entered into several limited term ancillary arrangements.

The Acquired Assets enhance the Company’s strategic focus to build a robust pipeline and commercialize quality drug candidates in China. The Company intends to select and commercialize certain products from the portfolio that have unique market and cost-effective manufacturing opportunities in China (and potentially in the U.S.).

The total purchase price for the Acquired Assets was $18.0 million in cash. The Company accounted for the purchase of the Acquired Assets as an asset acquisition (consisting of a concentrated group of similar identifiable assets, including ANDAs and API) following the guidance contain in Accounting Standards Update (“ASU”) 2017-01. The total purchase price, along with approximately $1.2 million of transaction expenses, was allocated to the Acquired Assets based on their relative fair values, as follows:

ANDAs	$	18,608,000
API		564,000
Total value	$	19,172,000

Of the total value allocated to the ANDAs, approximately $553,000 was immediately expensed as acquired in-process research and development since the underlying ANDAs have not been approved by the FDA, and of the total value allocated to the API, approximately $134,000 was immediately expensed as acquired in-process research and development since the Company does not intend to use all of the API. The allocated cost of the capitalized ANDAs will be amortized over their estimated useful lives of 13 years. The capitalized API will be expensed in the period it is used or if its value is otherwise impaired.

The fair values of certain acquired ANDAs were estimated using the discounted cash flow method (an income approach), which involves the use of Level 3 inputs such as estimates for projected sales, expenses, and cash flows, estimates of total addressable markets and market penetration rates, future sales growth and inflation rates, expected income and value-added tax rates, and a required rate of return adjusted for both industry and Company-specific risks, among other inputs. The fair values of the remaining ANDAs were estimated using a multiple of values method (an income approach), which involved using Level 3 inputs such as estimated addressable markets and market penetration rates. The fair value of the API was estimated using Level 2 inputs, such as quoted market prices for similar API from various suppliers or other sources. The ANDAs will be tested for impairment when events or circumstances indicate that the carrying value of the asset may not be recoverable; no such triggering events were identified during the period from the date of acquisition to March 31, 2018.

Intangible Assets

Intangible assets were acquired as part of the 2018 asset acquisition from Sandoz and include ANDAs for a total of 25 previously marketed generic products. These intangible assets were originally recorded at relative fair values based on the purchase price for the asset acquisition and are stated net of accumulated amortization.

The ANDAs are being amortized over their estimated useful lives of 13 years, using the straight-line method. Management reviews finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, in a manner similar to that for property and equipment. No impairment losses related to intangible assets were recognized in the three months ended March 31, 2018.

As discussed in Note 2, in January 2018, the Company purchased the Acquired Assets from Sandoz for a total purchase price of $18.0 million. The total purchase price, along with transaction expenses of approximately $1.2 million, was allocated to the ANDAs and API acquired based on their relative fair values. Net finite-lived intangible assets at March 31, 2018 consists of the following:

Asset		Gross Value				Accumulated Amortization				Estimated useful lives
ANDAs		$	18,054,985			$	(250,141	)		13 years

Expected future amortization expense is as follows for the years ending December 31:

2018 (remaining nine months)	$	1,041,634
2019		1,388,845
2020		1,388,845
2021		1,388,845
2022		1,388,845
2023 and thereafter		11,207,830

Foreign Currency Translation

The U.S. dollar is the reporting currency of the Company. Foreign currency denominated assets and liabilities of the Company and its foreign subsidiary are translated into U.S. dollars. Accordingly, assets and liabilities are translated using the exchange rates in effect at the consolidated balance sheet date and revenues and expenses at the rates of exchange prevailing when the transactions occurred, using an average periodic exchange rate. In 2017, remeasurement adjustments were included in income (loss). As discussed in Note 2, on January 26, 2018 the Company acquired a portfolio of ANDAs. Management believes that this transaction provides significant and permanent changes to its operations in China, and that it may allow its subsidiary in China to generate operating revenues from the China marketplace in the future and potentially sustain its own operations without the necessity of parent support. Accordingly, effective January 1, 2018, the functional currency of the Company’s subsidiary based in China has been changed to the local currency of the China Renminbi (“RMB”). The change in functional currency did not have a material impact on the consolidated financial statements.

Beginning January 1, 2018, translation gains and losses relating to the financial statements of the Company’s China subsidiary are included as accumulated other comprehensive income in the accompanying Condensed Consolidated Balance Sheets.

Investments

The Company has an equity investment in the publicly traded common stock of a company. Beginning on January 1, 2018 with the adoption of ASU 2016-01, the Company’s investment in this equity security is considered a trading security and is carried at its estimated fair value, with changes in fair value reported in the statement of operations each reporting period. The fair value of this security was measured using its quoted market price, a Level 1 input, and was approximately $1.3 million as of March 31, 2018.

In January 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-01, “Financial Instruments–Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.” In February 2018, the FASB issued ASU 2018-03, “Technical Corrections and Improvements to Financial Instruments–Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.” The accounting standards primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, it includes a clarification related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2017. The Company adopted ASU 2016-01 and ASU 2018-03 on January 1, 2018 and recorded a cumulative effect adjustment that decreased accumulated deficit by approximately $1.2 million. Effective January 1, 2018, the adoption date, changes in the fair value of the Company’s investments in equity securities are recognized in the statement of operations and comprehensive loss.

Inventories

Inventories consist of raw materials and are stated at the lower of cost or net realizable value. Cost is determined using an average cost method. The carrying value of raw materials inventory was approximately $430,000 as of March 31, 2018 and is included in “prepaid expenses and other assets” in the accompanying condensed consolidated balance sheets.

Research and Development

License Arrangements

The Company has certain product rights and perpetual exclusive licenses from Spectrum Pharmaceuticals, Inc. and certain of its affiliates (together referred to as “Spectrum”) to develop and commercialize the following commercial oncology drugs and drug candidates in the greater China region (which includes China, Taiwan, Hong Kong and Macau) (the “Territories”):

EVOMELA^® (melphalan) for Injection (“EVOMELA”);

MARQIBO^® (vinCRIStine sulfate LIPOSOME injection) (“MARQIBO”); and

ZEVALIN^® (ibritumomab tiuxetan) (“ZEVALIN”).

CASI is responsible for developing and commercializing these three drugs in the Territories, including the submission of import drug registration applications and conducting confirmatory clinical trials as needed.

The Company is in various stages of the regulatory and development process to obtain marketing approval for EVOMELA^®, MARQIBO^®, and ZEVALIN^® in its territorial region, with ZEVALIN^® commercially available in Hong Kong. In January 2016, the China Food and Drug Administration (CFDA) accepted for review the Company’s import drug registration application for MARQIBO^® and has completed the quality testing phase of the regulatory process and is currently in technical review by Center for Drug Evaluation (CDE) of the CFDA as part of the regulatory process. On March 10, 2016, Spectrum received notification from the FDA of the grant of approval of its New Drug Application (NDA) for EVOMELA^® primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. In December 2016, the CFDA accepted for review the Company’s import drug registration application for EVOMELA^® and in 2017 has granted priority review of the import drug registration clinical trial application (CTA). EVOMELA^® has completed the quality testing phase of the regulatory process, as well as the technical review by Center for Drug Evaluation (CDE) of the CFDA, and it has recently been evaluated under a CFDA CDE Advisory Committee meeting and is currently waiting for the result. In 2017, the CFDA accepted for review the Company’s import drug registration for ZEVALIN^® including both the antibody kit and the radioactive Yttrium-90 component.

Note Payable

As part of the license arrangements with Spectrum (see Note 8), the Company issued to Spectrum a $1.5 million 0.5% secured promissory note originally due March 17, 2016 which was subsequently amended and extended to September 17, 2019. All other terms remain the same. The promissory note was recorded initially at its fair value, giving rise to a discount of approximately $136,000; the promissory note is presented as note payable, net of discount in the accompanying condensed consolidated balance sheets. For the three months ended March 31, 2018 and 2017, the Company recognized $177 and $1,869 of non-cash interest expense, respectively, related to the amortization of the debt discount, using the effective interest rate method.

10.

Stockholders’ Equity

Securities Purchase Agreements

As described in Note 1, in March 2018, the Company entered into securities purchase agreements (the “Securities Purchase Agreements”) with certain institutional investors, accredited investors and current stockholders, pursuant to which the Company issued 15,432,091 shares of its common stock with accompanying warrants to purchase 6,172,832 shares of its common stock in a $50 million private placement. The Company received gross proceeds of $29.3 million through March 31, 2018 and issued 9,043,204 shares of common stock with accompanying warrants to purchase 3,617,279 shares of its common stock. The Company received the remaining gross proceeds of $20.7 million in April 2018 and issued 6,388,887 shares of common stock with accompanying warrants to purchase 2,555,553 shares of its common stock. The purchase price for each share of common stock and warrant was $3.24. The warrants will become exercisable on September 17, 2018 at a $3.69 per share exercise price, and will expire on March 21, 2023. The fair value of the warrants issued is $15,062,000, or $2.44 per warrant, calculated using the Black-Scholes-Merton valuation model with a contractual life of 5 years, an assumed volatility of 75.4%, and a risk-free interest rate of 2.69%. The Securities Purchase Agreements and warrants each include additional customary representations, warranties and covenants. The Company also agreed to file a resale registration within 120 days following the closing covering the shares of common stock issued and the shares of common stock underlying the warrants.

Common Stock Sales Agreement

On February 23, 2018, the Company entered into a Common Stock Sales Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“HCW”). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time, at its option, shares of the Company’s common stock through HCW, as sales agent, with an aggregate sales price of up to $25 million (the “Shares”).

Any sales of Shares pursuant to the Sales Agreement will be made under the Company’s effective “shelf” registration statement (the “Registration Statement”) on Form S-3 (File No. 333-222046) which became effective on December 22, 2017 and the related prospectus supplement and the accompanying prospectus, as filed with the Securities and Exchange Commission (the “SEC”) on February 23, 2018.

In March 2018, the Company issued 143,248 Shares under the Sales Agreement resulting in net proceeds to the Company of approximately $475,000. As of March 31, 2018, approximately $24.5 million remained available under the Sales Agreement.

11.

Net Loss Per Share

Net loss per share (basic and diluted) was computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding. Outstanding stock options and warrants totaling 11,902,287 and 9,305,165 as of March 31, 2018, respectively, were anti-dilutive and, therefore, were not included in the computation of weighted average shares used in computing diluted loss per share.

12.

Stock-Based Compensation and Warrants

The Company has adopted incentive and nonqualified stock option plans for executive, scientific and administrative personnel of the Company as well as outside directors and consultants. As of March 31, 2018, there are 11,902,287 shares issuable under options previously granted and currently outstanding, with exercise prices ranging from $0.86 to $7.37. Options granted under the plans generally vest over periods varying from immediately to one to three years, are not transferable and generally expire ten years from the date of grant. As of March 31, 2018, 2,478,048 shares remained available for grant under the Company’s 2011 Long-Term Incentive Plan. On March 13, 2018, upon the recommendation of the Compensation Committee of the Board of Directors (the “Board”), the Board approved a grant of stock options to the Company’s Executive Chairman exercisable for 1 million shares of common stock that will vest and become exercisable on the first anniversary date of the grant. In addition, the Board approved the grant of a performance-based option covering 4 million shares of common stock that will vest if, within 18 months of the date of grant, specific operational and strategic milestones are achieved. Both grants are conditioned upon stockholder approval at the 2018 Annual Meeting of Stockholders.

The Company records compensation expense associated with stock options and other equity-based compensation in accordance with provisions of authoritative guidance. Compensation costs are recognized over the requisite service period, which is generally the option vesting term of up to three years. Awards with performance conditions will be expensed if it is probable that the performance condition will be achieved. There was no expense recorded for share awards with performance conditions during the three months ended March 31, 2018 and 2017.

The Company’s net loss for the three months ended March 31, 2018 and 2017 includes $260,040 and $156,250, respectively, of non-cash compensation expense related to the Company’s share-based compensation awards. The compensation expense related to the Company’s share-based compensation arrangements is recorded as components of general and administrative expense and research and development expense, as follows:

	Three Months period ended March 31,

	2018		2017
Research and development	$	103,767	$	67,198
General and administrative		156,273		89,052
Share-based compensation expense	$	260,040	$	156,250
Net share-based compensation expense, per common share:
Basic and diluted	$	0.004	$	0.003

The Company uses the Black-Scholes-Merton valuation model to estimate the fair value of service based and performance based stock options granted to employees. Option valuation models, including Black-Scholes-Merton, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant date fair value of an award. Following are the weighted-average assumptions used in valuing the stock options granted to employees during the three-month periods ended March 31, 2018 and 2017:

	Three Month Period ended March 31,
	2018			2017
Expected volatility		79.51	%		81.07	%
Risk free interest rate		2.63	%		2.03	%
Expected term of option		6.31	years		5.81	years
Expected dividend yield		0.00	%		0.00	%

The weighted average fair value of stock options granted during the three-month periods ended March 31, 2018 and 2017 were $2.61 and $1.04, respectively.

A summary of the Company's stock option plans and of changes in options outstanding under the plans during the three-month period ended March 31, 2018 is as follows:

	Number of Options			Weighted Average Exercise Price
Outstanding at January 1, 2018		11,585,315		$	1.42
Exercised		(57,214	)	$	1.71
Granted		391,000		$	3.70
Expired		-		$	-
Forfeited		(16,814	)	$	3.05
Outstanding at March 31, 2018		11,902,287		$	1.50
Exercisable at March 31, 2018		8,630,758		$	1.58

Cash received from option exercises under all share-based payment arrangements for the three months ended March 31, 2018 was $98,022. There were no option exercises during the three months ended March 31, 2017.

Warrants

Warrants issued generally expire after 2-5 years from the date of issuance. Stock warrant activity is as follows:

	Number of Warrants			Weighted Average Exercise Price
Outstanding at January 1, 2018		6,264,016		$	2.23
Issued		3,617,279		$	3.69
Exercised		(576,130	)	$	1.69
Expired		-		$	-
Outstanding at March 31, 2018		9,305,165		$	2.83
Exercisable at March 31, 2018		4,049,380		$	1.69

Cash received from warrants exercised during the three months ended March 31, 2018 was $973,660. There were no warrants exercised during the three months ended March 31, 2017.

13.

Income Taxes

At December 31, 2017, the Company had a $3.2 million unrecognized tax benefit. The Company recorded a full valuation allowance on the net deferred tax asset recognized in the consolidated financial statements as of December 31, 2017.

During the three months ended March 31, 2018, there were no material changes to the measurement of unrecognized tax benefits in various taxing jurisdictions. The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense.

The tax returns for all years in the Company’s major tax jurisdictions are not settled as of March 31, 2018. Due to the existence of tax attribute carryforwards (which are currently offset by a full valuation allowance), the Company treats all years’ tax positions as unsettled due to the taxing authorities’ ability to modify these attributes.

14.

Related Party Transactions

The Company has supply agreements with Spectrum, for the purchase of EVOMELA^®, MARQIBO^®, and ZEVALIN^®, in China for quality testing purposes to support CASI’s application for import drug registration and for commercialization purposes. The former CEO of Spectrum and current board member of Spectrum is also a member of CASI’s Board of Directors. All amounts payable to Spectrum for material purchases have been paid as of March 31, 2018. There were no materials purchases from Spectrum for the three months ended March 31, 2018 or 2017.

15.

New Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect and that may impact the Company’s consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 supersedes existing lease guidance, including Accounting Standards Codification (ASC) 840 - Leases. Among other things, the new standard requires recognition of a right-of-use asset and liability for future lease payments for contracts that meet the definition of a lease. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted. The standard must be applied using a modified retrospective approach. The Company is currently evaluating the effect that the adoption of this ASU will have on its consolidated financial statements.

In January 2017, the FASB issued ASU No. 2017-01 “Clarifying the Definition of a Business” (Topic 805). The amendments in the update provide a screen to determine when a set is not a business. If the screen is not met, the amendments in the update (1) require that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) remove the evaluation of whether a market participant could replace missing elements. The amendments provide a framework to assist entities in evaluating whether both an input and a substantive process are present. Lastly, the amendments in the update narrow the definition of the term output so that the term is consistent with how outputs are described in Topic 606. The ASU is effective for annual periods and interim periods within those annual periods beginning after December 15, 2017; earlier adoption is permitted under certain criteria. The Company adopted this ASU on January 1, 2018. While this ASU did not have a material effect on the Company’s financial statements on the date of adoption, the Company did follow the new guidance in determining that its acquisition of ANDAs from Sandoz, Inc. in January 2018 was an asset acquisition. See Note 2.

In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting. ASU 2017-09 provides clarification on when modification accounting should be used for changes to the terms or conditions of a share-based payment award. This ASU does not change the accounting for modifications but clarifies that modification accounting guidance should only be applied if there is a change to the value, vesting conditions, or award classification and would not be required if the changes are considered non-substantive. This ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted ASU 2017-09 in the first quarter of 2018 and the adoption of this ASU did not have a material effect on the consolidated financial statements.

There are no other recently issued accounting pronouncements that are expected to have a material effect on the Company's financial position, results of operations or cash flows.

16.

Commitments

In March 2018, the Company committed to a purchase obligation of EVOMELA^®from Spectrum for approximately $5.5 million.

In April 2018, the Company entered into a lease agreement for office space in China that continues through April 2021. Future minimum lease payments are approximately $334,000 in 2018, $561,900 in 2019, $561,900 in 2020 and $140,500 in 2021.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

OVERVIEW

We are a U.S. based biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world. We intend to execute our plan to become a leading pharmaceutical company with a substantial market share in China. We are headquartered in Rockville, Maryland and have a wholly owned subsidiary and R&D operations in Beijing, China.

Our product pipeline features (1) EVOMELA^®, MARQIBO^®, and ZEVALIN^®, all U.S. FDA approved drugs in-licensed from Spectrum Pharmaceuticals, Inc. for China regional rights, and currently in various stages in the regulatory process for market approval in China, (2) an acquired portfolio of 25 FDA-approved abbreviated new drug applications (“ANDAs”) and four pipeline ANDAs that are pending FDA approval, from which we will prioritize a select subset for product registration and commercialization in China, (3) our proprietary drug candidate, ENMD-2076, currently in Phase 2 clinical development, and (4) CASI-001 and CASI-002, proprietary early-stage candidates in immuno-oncology in preclinical development.

We believe our pipeline reflects a risk-balanced approach between products in various stages of development, and between products that we develop ourselves and those that we develop with our partners for the China regional market. We intend to continue building a significant product pipeline of high quality, cost-effective pharmaceuticals, as well as innovative drug candidates that we will commercialize alone in China and with partners for the rest of the world. For in-licensed products, the Company uses a market-oriented approach to identify pharmaceutical candidates that it believes have the potential for gaining widespread market acceptance, either globally or in China, and for which development can be accelerated under the Company’s drug development strategy. For our FDA-approved ANDAs, we intend to select and commercialize certain products from the portfolio that offer unique market and cost-effective manufacturing opportunities in China and/or in the U.S. For ENMD-2076, our current development is focused on niche and orphan indications.

Our primary research and development focus is to acquire high quality, cost-effective medicines, as well as to in-license clinical-stage and late-stage drug candidates so that we can immediately employ our U.S. and China drug development model to accelerate commercialization, and clinical and regulatory progress. In addition to our high quality, cost-effective medicines, and our clinical-and late-stage approach for innovative products, we have other potential drug candidates in preclinical development which we will continue to evaluate in 2018. The implementation of our plans will include leveraging our resources in both the United States and China. In order to capitalize on the drug development and capital resources available in China, we are doing business in China through our wholly-owned China-based subsidiary that will execute the China portion of our drug development strategy, including conducting clinical trials in China, pursuing local funding opportunities and strategic collaborations, and implementing our transition to a commercial enterprise.

Since inception, the Company has incurred significant losses from operations and has incurred an accumulated deficit of $455.1 million. The Company restructured its business in 2012 in connection with an investment led by one of the Company’s largest stockholders, followed by implementation of a name change to reflect its core mission and business strategy. The Company expects to continue to incur operating losses for the foreseeable future due to, among other factors, its continuing clinical activities. In March 2018, the Company entered into securities purchase agreements pursuant to which the Company issued 15,432,091 shares of its common stock with accompanying warrants to purchase 6,172,832 shares of its common stock in a $50 million private placement (the “2018 Financing”). The Company received gross proceeds of $29.3 million in March 2018 and received additional gross proceeds of $20.7 million in April 2018. The 2018 Financing closing included an investment from ETP Global Fund, L.P., a healthcare investment fund. The managing member of Emerging Technology Partners, LLC, which is the general partner of ETP Global Fund, L.P., is also the Executive Chairman of the Company. The 2018 Financing also included an investment from IDG-Accel China Growth Fund III L.P. (“IDG-Accel Growth”) and IDG-Accel China III Investors L.P. (“IDG-Accel Investors”). A director and shareholder of IDG-Accel China Growth Fund GP III Associates Ltd., which is the ultimate general partner of IDG-Accel Growth and IDG-Accel Investors, is also a board member of the Company. In October 2017, the Company entered into securities purchase agreements for an approximately $23.8 million strategic financing. The Company held its initial closing on October 17, 2017, a second closing on October 23, 2017 and a final closing on November 20, 2017 (collectively, the “2017 Closings”) and received approximately $23.4 million in net proceeds. Net proceeds from the 2018 Financing and the 2017 Closings are being used to prepare for the anticipated launch of the Company’s first commercial product in China, to support the Company’s business development activities, to advance the development of the Company’s pipeline, support its marketing and commercial planning activities, and for other general corporate purposes.

As a result of the 2018 Financing and the 2017 Closings, the Company believes that it has sufficient resources to fund its operations at least through May 15, 2019. As of March 31, 2018, approximately $20.9 million of the Company’s cash balance was held by CASI China. We intend to continue to exercise tight controls over operating expenditures. In developing drug candidates, we intend to use and leverage resources available to us in both the United States and China. We intend to pursue additional financing opportunities as well as opportunities to raise capital through forms of non- or less- dilutive arrangements, such as partnerships and collaborations with organizations that have capabilities and/or products that are complementary to our capabilities and products in order to continue the development of our product candidates that we intend to pursue to commercialization.

Additional funds raised by issuing equity securities may result in dilution to existing stockholders.

CRITICAL ACCOUNTING POLICIES AND THE USE OF ESTIMATES

The preparation of our financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Our critical accounting policies, including the items in our financial statements requiring significant estimates and judgments, are as follows:

Research and Development - Research and development expenses consist primarily of compensation and other expenses related to research and development personnel, research collaborations, costs associated with pre-clinical testing and clinical trials of the Company’s product candidates, including the costs of manufacturing drug substance and drug product, regulatory maintenance costs, and facilities expenses, along with the amortization of acquired ANDAs. Research and development costs are expensed as incurred.

Expenses for Clinical Trials - Expenses for clinical trials are incurred from planning through patient enrollment to reporting of the data. We estimate expenses incurred for clinical trials that are in process based on patient enrollment and based on clinical data collection and management. Costs that are associated with patient enrollment are recognized as each patient in the clinical trial completes the enrollment process. Estimated clinical trial costs related to enrollment can vary based on numerous factors, including expected number of patients in trials, the number of patients that do not complete participation in a trial, and when a patient drops out of a trial. Costs that are based on clinical data collection and management are recognized in the reporting period in which services are provided. In the event of early termination of a clinical trial, we accrue an amount based on estimates of the remaining non-cancelable obligations associated with winding down the clinical trial.

Stock-Based Compensation - All share-based payment transactions are recognized in the consolidated financial statements at their fair values. Compensation expense associated with service and performance condition-based stock options and other equity-based compensation is recorded in accordance with provisions of authoritative guidance. The fair value of awards for which fair values are calculated using the Black-Scholes-Merton option pricing model is generally being amortized on a straight-line basis over the requisite service period and is recognized based on the proportionate amount of the requisite service period that has been rendered during each reporting period. Share-based awards granted to employees with a performance condition are measured based on the probable outcome of that performance condition during the requisite service period. Such an award with a performance condition will be expensed if it is probable that a performance condition will be achieved. There was no expense recorded for share awards with performance conditions during the three months ended March 31, 2018 and 2017. Using the straight-line expense attribution method over the requisite service period, which is generally the option vesting term ranging from immediately to one to three years, share-based compensation expense recognized for the three months ended March 31, 2018 and 2017 totaled approximately $260,000 and $156,000, respectively.

The determination of fair value of stock-based payment awards on the date of grant using the Black-Scholes-Merton valuation model is affected by our stock price, as well as the input of other subjective assumptions. These assumptions include, but are not limited to, the expected forfeiture rate and expected term of stock options and our expected stock price volatility over the term of the awards. Changes in the assumptions can materially affect the fair value estimates.

Any future changes to our share-based compensation strategy or programs would likely affect the amount of compensation expense recognized.

RESULTS OF OPERATIONS

For the Three Months Ended March 31, 2018 and 2017.

Revenues and Cost of Product Sales. There were no revenues recorded for the three months ended March 31, 2018 and 2017.

Research and Development Expenses. Our research and development expenses for the three months ended March 31, 2018 totaled approximately $1,697,000 and $1,049,000 for the corresponding 2017 period. Included in our research and development expenses for the three-month period ended March 31, 2018 are direct project costs of $441,000 related to our ANDAs acquired in January 2018, $113,000 for ENMD-2076, $142,000 for drugs in-licensed from Spectrum, and $498,000 for preclinical development activities primarily in China. The 2017 research and development expenses for the comparable period included direct project costs of $274,000 for ENMD-2076, $188,000 for drugs in-licensed from Spectrum, and $242,000 for preclinical development activities primarily in China.

At March 31, 2018, and, since acquired, accumulated direct project expenses for our ANDAs acquired in January 2018 totaled $441,000; $28,624,000 for ENMD-2076; $4,678,000 for drugs in-licensed from Spectrum; and for preclinical development activities primarily in China, accumulated project expenses totaled $3,854,000. Our research and development expenses also include non-cash stock-based compensation totaling $104,000 for the three-months ended March 31, 2018 and $67,000 for the corresponding 2017 period. The balance of our research and development expenditures includes facility costs and other departmental overhead, expenditures related to the non-clinical support of our programs, and non-cash amortization expense of acquired ANDAs.

We expect the majority of our research and development expenses in 2018 to be devoted to advancing our in-licensed products towards market approval in China, the technology transfer activities and regulatory support associated with our ANDA portfolio, and our early-stage candidates in preclinical development. We expect our expenses in 2018 to increase based on our commercial and clinical development plan. Completion of clinical development may take several years or more, but the length of time generally varies substantially according to the type, complexity, novelty and intended use of a product candidate.

We estimate that clinical trials of the type we generally conduct are typically completed over the following timelines:

Global FDA Trial:

*CLINICAL PHASE*		*ESTIMATED* *COMPLETION* *PERIOD*
Phase 1		1-2 Years
Phase 2		2-3 Years
Phase 3		2-4 Years

Local CFDA Trial:

*CLINICAL PHASE*		*ESTIMATED* *COMPLETION* *PERIOD*
Phase 1		1 Year
Phase 2		2 Years
Phase 3		2-3 Years

The duration and the cost of clinical trials may vary significantly over the life of a project as a result of differences arising during the clinical trial protocol, including, among others, the following:

the number of patients that ultimately participate in the trial;

the duration of patient follow-up that seems appropriate in view of the results;

the number of clinical sites included in the trials; and

the length of time required to enroll suitable patient subjects.

We test our potential product candidates in numerous preclinical studies to identify indications for which they may be product candidates. We may conduct multiple clinical trials to cover a variety of indications for each product candidate. As we obtain results from trials, we may elect to discontinue clinical trials for certain indications in order to focus our resources on more promising indications.

Our proprietary product candidates have also not yet achieved regulatory approval, which is required before we can market them as therapeutic products. In order to proceed to subsequent clinical trial stages and to ultimately achieve regulatory approval, regulatory agencies must conclude that our clinical data establish safety and efficacy. Historically, the results from preclinical testing and early clinical trials have often not been predictive of results obtained in later clinical trials. A number of new drugs and biologics have shown promising results in clinical trials, but subsequently failed to establish sufficient safety and efficacy data to obtain necessary regulatory approvals.

Our business strategy includes being opportunistic with collaborative arrangements with third parties to complete the development and commercialization of our product candidates. In the event that third parties take over the clinical trial process for one of our product candidates, the estimated completion date would largely be under the control of that third party rather than us. We cannot forecast with any degree of certainty which proprietary products or indications, if any, will be subject to future collaborative arrangements, in whole or in part, and how such arrangements would affect our capital requirements.

As a result of the uncertainties discussed above, among others, we are unable to estimate the duration and completion costs of our research and development projects. Our inability to complete our research and development projects in a timely manner or our failure to enter into collaborative agreements, when appropriate, could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to seek additional, external sources of financing from time to time in order to continue with our business strategy. There can be no assurance that we will be able to successfully access external sources of financing in the future. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business.

Research and development expenses consist primarily of compensation and other expenses related to research and development personnel, research collaborations, costs associated with internal and contract preclinical testing and clinical trials of our product candidates, including the costs of manufacturing drug substance and drug product, regulatory maintenance costs, facilities expenses, and amortization expense of acquired ANDAs. Overall research and development expenses increased to $1,697,000 during the three months ended March 31, 2018 from $1,049,000 for the corresponding period in 2017. The fluctuations in research and development expenditures during the three months ended March 31, 2018 were specifically impacted by the following:

Outside Services – We utilize outsourcing to conduct our product development activities. In the three-month period ended March 31, 2018, we expended $343,000 on outside service activities versus $198,000 in the same 2017 period. The increase in 2018 as compared to 2017 reflects regulatory costs associated with our ANDAs acquired in January 2018.

Clinical Trial Costs – Clinical trial costs, which include clinical site fees, monitoring costs and data management costs, decreased to $77,000 in the three months ended March 31, 2018 from $166,000 in the three-month period ended March 31, 2017. This decrease primarily relates to higher patient costs and clinical trial management costs associated with our Phase 2 clinical trial in advanced fibrolamellar carcinoma (FLC) during the 2017 period compared to the 2018 period as enrollment has completed.

Lab Supplies – Laboratory supplies associated with our pre-clinical activities for the three-month period ended March 31, 2018 increased to $101,000 from $40,000 during the same period in 2017 due to the expansion of activities in our China research and development lab.

Contract Manufacturing Costs – The costs of manufacturing the material used in clinical trials for our product candidates is reflected in contract manufacturing. These costs include bulk manufacturing, encapsulation and fill and finish services, product release costs and storage fees. Contract manufacturing costs for the three months ended March 31, 2018 decreased to $5,000 from $12,000 during the same period in 2017 due to the timing of stability testing reporting.

Personnel Costs – Personnel costs increased to $668,000 in the three-month period ended March 31, 2018 from $386,000 in the corresponding 2017 period. This variance is primarily attributed to increased salary and benefit costs associated with new employees hired in China and a new Chief Medical Officer in the U.S. beginning in April 2017.

Also reflected in our 2018 research and development expenses are outsourced consultant costs of $34,000, facility and related expenses of $157,000, and amortization of acquired ANDAs of $250,000. In the corresponding 2017 period, these expenses totaled $95,000, $103,000, and $0, respectively. The decrease in outsourced consultant costs reflects lower costs associated with clinical trial management and evaluation and regulatory activities in the U.S. The increase in facilities and related expenses is due to new leased lab space in China in February 2017. The increase in amortization of acquired ANDAs is due to the January 2018 acquisition of ANDAs.

General and Administrative Expenses. General and administrative expenses include compensation and other expenses related to finance, business development and administrative personnel, professional services and facilities.

General and administrative expenses increased to $1,303,000 in the three-month period ended March 31, 2018 from $644,000 in the corresponding 2017 period. This variance is primarily attributed to an increase in salary, benefits and recruitment expense totaling approximately $182,000 in China primarily related to sales and marketing efforts to prepare for the anticipated launch of the Company’s first commercial product in China, as well as other general and administrative functions. Additionally, non-cash stock-based compensation expense increased by $67,000. The balance of the increase during the 2018 period is due to increased costs associated with business development, investor and public relations activities, and an increase in legal and other professional services fees.

Acquired In-process Research and Development. In January 2018, we acquired a portfolio of 29 ANDAs, including 25 FDA-approved ANDAs and four pipeline ANDAs that are pending FDA approval, limited quantities of API, and certain manufacturing and other information related to the products (collectively, the ANDAs, API and other information is referred to as the “Acquired Assets”). The total purchase price for the Acquired Assets was $18.0 million in cash. We accounted for the purchase of the Acquired Assets as an asset acquisition (consisting of a concentrated group of similar identifiable assets, including ANDAs and API). The total purchase price, along with approximately $1.2 million of transaction expenses, was allocated to the Acquired Assets based on their relative fair values. Of the total value allocated to the ANDAs, approximately $553,000 was immediately expensed as acquired in-process research and development since the underlying ANDAs have not been approved by the FDA, and of the total value allocated to the API, approximately $134,000 was immediately expensed as acquired in-process research and development since the Company does not intend to use all the API.

Interest income, net. Interest income, net for the three months ended March 31, 2018 and 2017 was $6,729 and $142, respectively. This includes interest income of $8,781 and $3,886, respectively, offset by interest expense on our note payable of $1,875 for both periods; and non-cash interest of $177 and $1,869, respectively, representing the amortization of the debt discount.

Other income. Other income for the three months ended March 31, 2018 was $89,713, representing unrealized gains on the Company’s equity investment securities.

Change in fair value of contingent rights. The Contingent Rights issued to Spectrum in connection with the license arrangements are considered derivative liabilities and were recorded initially at their estimated fair value and are marked to market each reporting period until settlement. The Contingent Rights were fully settled during 2017, so there was no change in the fair value of the Contingent Right for the three months ended March 31, 2018. The change in fair value of the Contingent Rights for the three months ended March 31, 2017 was $6,874.

LIQUIDITY AND CAPITAL RESOURCES

To date, we have been engaged primarily in research and development activities. As a result, we have incurred and expect to continue to incur operating losses in 2018 and the foreseeable future before we commercialize any products and penetrate significant markets such as China. Based on our current plans, we expect our current available cash and cash equivalents to meet our cash requirements for at least through May 15, 2019.

We will require significant additional funding to fund operations until such time, if ever, we become profitable. We intend to augment our cash balances by pursuing other forms of capital infusion, including strategic alliances or collaborative development opportunities with organizations that have capabilities and/or products that are complementary to our capabilities and products in order to continue the development of our potential product candidates that we intend to pursue to commercialization. If we seek strategic alliances, licenses, or other alternative arrangements, such as arrangements with collaborative partners or others, to raise further financing, we may need to relinquish rights to certain of our existing product candidates, or products we would otherwise seek to develop or commercialize on our own, or to license the rights to our product candidates on terms that are not favorable to us.

We will continue to seek to raise additional capital to fund our commercialization efforts, research and development, and the clinical development of ENMD-2076 and new product candidates, if any. We intend to explore one or more of the following alternatives to raise additional capital:

selling additional equity securities;

out-licensing product candidates to one or more corporate partners;

completing an outright sale of non-priority assets; and/or

engaging in one or more strategic transactions.

We also will continue to manage our cash resources prudently and cost-effectively.

There can be no assurance that adequate additional financing under such arrangements will be available to us on terms that we deem acceptable, if at all. If additional funds are raised by issuing equity securities, dilution to existing stockholders may result, or the equity securities may have rights, preferences, or privileges senior to those of the holders of our common stock. If we fail to obtain additional capital when needed, we may be required to delay or scale back our commercialization efforts, our advancement of the Spectrum products, and our Phase 2 plans for ENMD-2076 or plans for other product candidates, if any.

At March 31, 2018, we had cash and cash equivalents of approximately $49.9 million, with working capital of approximately $50.0 million. As of March 31, 2018, approximately $20.9 million of the Company’s cash balance was held by the Company’s wholly-owned subsidiary in China.

As a result of the Company’s acquisition of a portfolio of ANDAs, we believe that this transaction provides significant and permanent changes to our operations in China, and that may allow our subsidiary in China to generate operating revenues from the China marketplace in the future and potentially to sustain its own operations without the necessity of parent support. Accordingly, effective January 1, 2018, the functional currency of the Company’s subsidiary based in China has been changed to the local currency of the China RMB. The change in functional currency did not have a material impact on the consolidated financial statements.

FINANCING ACTIVITIES

“Shelf” Registration Statement

On December 13, 2017, we filed a Form S-3 registration statement with the SEC utilizing a “shelf” registration process. On December 22, 2017, the Form S-3 registration statement was declared effective by the SEC. Pursuant to this shelf registration statement, we may sell debt or equity securities in one or more offerings up to a total public offering price of $100 million. We believe that this shelf registration statement currently provides us additional flexibility with regard to potential financings that we may undertake when market conditions permit or our financial condition may require.

Securities Purchase Agreements

As discussed above, in March 2018, the Company entered into securities purchase agreements (the “Securities Purchase Agreements”) with certain institutional investors, accredited investors and current stockholders, pursuant to which the Company issued 15,432,091 shares of its common stock with accompanying warrants to purchase 6,172,832 shares of its common stock in a $50 million private placement. The Company received gross proceeds of $29.3 million as of March 31, 2018 and received the remaining gross proceeds of $20.7 million in April 2018. The purchase price for each share of common stock and warrant was $3.24. The warrants will become exercisable on September 17, 2018 at a $3.69 per share exercise price, and will expire on March 21, 2023. The fair value of the warrants issued is $15,062,000, or $2.44 per warrant, calculated using the Black-Scholes-Merton valuation model with a contractual life of 5 years, an assumed volatility of 75.4%, and a risk-free interest rate of 2.69%. The Securities Purchase Agreements and warrants each include additional customary representations, warranties and covenants. The Company also agreed to file a resale registration within 120 days following the closing covering the shares of common stock issued and the shares of common stock underlying the warrants.

Common Stock Sales Agreement

INFLATION AND INTEREST RATE CHANGES

Management does not believe that our working capital needs are sensitive to inflation and changes in interest rates.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The primary objective of our investment activities is to preserve our capital until it is required to fund operations while at the same time maximizing the income we receive from our investments without incurring investment market volatility risk. Our investment income is sensitive to the general level of U.S. interest rates. In this regard, changes in the U.S. interest rates affect the interest earned on our cash and cash equivalents. Due to the short-term nature of our cash and cash equivalent holdings, a 10% movement in market interest rates would not materially impact the total fair market value of our portfolio as of March 31, 2018.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Based on an evaluation under the supervision and with the participation of the Company’s management, the Company’s Chief Executive Officer and Principal Accounting Officer have concluded that the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) were effective as of March 31, 2018 to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms and (ii) accumulated and communicated to the Company’s management, including its Chief Executive Officer and Principal Accounting Officer, as appropriate to allow timely decisions regarding required disclosure.

We believe that a controls system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

Changes in Internal Control Over Financial Reporting

There were no changes in the Company’s internal control over financial reporting that occurred during the quarter ended March 31, 2018 that have materially affected or are reasonably likely to materially affect the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

We are subject in the normal course of business to various legal proceedings in which claims for monetary or other damages may be asserted. Management does not believe such legal proceedings, unless otherwise disclosed herein, are material.

ITEM 1A. RISK FACTORS

For information regarding factors that could affect the Company’s results of operations, financial condition and liquidity, see the risk factors discussion set forth in Item 1A of CASI’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and the information under “Special Note Regarding Forward-Looking Statements” included in this report. There have been no material changes to our risk factors from those disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4.

REMOVED AND RESERVED

ITEM 5.

OTHER INFORMATION

Not applicable.

ITEM 6.

EXHIBITS

1.1		Common Stock Sales Agreement by and between the Company and H.C. Wainwright & Co. dated February 23, 2018 (incorporated by reference to Exhibit 1.1 to the Company’s Form 8-K filed with the Securities and Exchange Commission on February 23, 2018)
31.1		Rule 13a-14(a) Certification of Chief Executive Officer*
31.2		Rule 13a-14(a) Certification of Principal Accounting Officer*
32.1		Section 1350 Certification of Chief Executive Officer*
32.2		Section 1350 Certification of Principal Accounting Officer*
101		The following financial information from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, formatted in eXtensible Business Reporting Language (XBRL): (i) Unaudited Condensed Consolidated Balance Sheets at March 31, 2018 and December 31, 2017, (ii) Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2018 and 2017, (iii) Unaudited Condensed Consolidated Statement of Stockholders’ Equity for the Three Months Ended March 31, 2018, (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2018 and 2017, and (v) Notes to Unaudited Condensed Consolidated Financial Statements.*

* Filed Herewith

EXHIBIT INDEX

1.1		Common Stock Sales Agreement by and between the Company and H.C. Wainwright & Co. dated February 23, 2018 (incorporated by reference to Exhibit 1.1 to the Company’s Form 8-K filed with the Securities and Exchange Commission on February 23, 2018)
31.1		Rule 13a-14(a) Certification of Chief Executive Officer*
31.2		Rule 13a-14(a) Certification of Principal Accounting Officer*
32.1		Section 1350 Certification of Chief Executive Officer*
32.2		Section 1350 Certification of Principal Accounting Officer*
101		The following financial information from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, formatted in eXtensible Business Reporting Language (XBRL): (i) Unaudited Condensed Consolidated Balance Sheets at March 31, 2018 and December 31, 2017, (ii) Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2018 and 2017, (iii) Unaudited Condensed Consolidated Statement of Stockholders’ Equity for the Three Months Ended March 31, 2018, (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2018 and 2017, and (v) Notes to Unaudited Condensed Consolidated Financial Statements.*

* Filed Herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CASI PHARMACEUTICALS, INC.
	(Registrant)

Date: May 15, 2018	/s/ Ken K. Ren
	Ken K. Ren
	Chief Executive Officer

Date: May 15, 2018	/s/ Sara B. Capitelli
	Sara B. Capitelli
	Principal Accounting Officer

EX-31.1 2 tv493209_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, Ken K. Ren, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CASI Pharmaceuticals, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the condensed consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of condensed consolidated financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 15, 2018

/s/ Ken K. Ren
Ken K. Ren
Chief Executive Officer

EX-31.2 3 tv493209_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL ACCOUNTING OFFICER

I, Sara B. Capitelli, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CASI Pharmaceuticals, Inc.;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 15, 2018

/s/ Sara B. Capitelli
Sara B. Capitelli
Principal Accounting Officer

EX-32.1 4 tv493209_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION BY CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CASI Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ken K. Ren, as Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by the Report.

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

Date: May 15, 2018		/s/ Ken K. Ren
		Ken K. Ren
		Chief Executive Officer

EX-32.2 5 tv493209_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION BY PRINCIPAL ACCOUNTING OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CASI Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sara B. Capitelli, as Principal Accounting Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by the Report.

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

Date: May 15, 2018		/s/ Sara B. Capitelli
		Sara B. Capitelli
		Principal Accounting Officer

EX-101.INS 6 casi-20180331.xml XBRL INSTANCE DOCUMENT 0000895051 2017-01-01 2017-03-31 0000895051 2018-01-01 2018-03-31 0000895051 2018-03-01 2018-03-31 0000895051 2018-03-31 0000895051 2018-05-08 0000895051 2017-12-31 0000895051 2016-12-31 0000895051 2017-03-31 0000895051 us-gaap:PreferredStockMember 2018-01-01 2018-03-31 0000895051 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0000895051 us-gaap:TreasuryStockMember 2018-01-01 2018-03-31 0000895051 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000895051 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000895051 casi:InvestorsMember 2017-10-01 2017-10-17 0000895051 casi:CasiChinaMember 2018-03-31 0000895051 casi:SpectrumPharmaceuticalsMember 2018-03-31 0000895051 casi:SpectrumPharmaceuticalsMember 2018-01-01 2018-03-31 0000895051 us-gaap:InvestorMember 2018-03-31 0000895051 us-gaap:MaximumMember casi:HcWainwrightCoLlcMember 2018-02-23 0000895051 casi:LongTermIncentivePlan2011Member 2018-03-31 0000895051 casi:LongTermIncentivePlan2011Member us-gaap:MinimumMember 2018-01-01 2018-03-31 0000895051 casi:LongTermIncentivePlan2011Member us-gaap:MaximumMember 2018-01-01 2018-03-31 0000895051 casi:ExecutiveChairmanMember 2018-03-13 0000895051 casi:ExecutiveChairmanMember casi:PerformanceBasedOptionMember 2018-03-13 0000895051 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-03-31 0000895051 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-03-31 0000895051 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-03-31 0000895051 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-03-31 0000895051 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0000895051 us-gaap:EmployeeStockOptionMember 2018-03-31 0000895051 us-gaap:MinimumMember 2018-01-01 2018-03-31 0000895051 us-gaap:MaximumMember 2018-01-01 2018-03-31 0000895051 casi:SecondClosingMember 2017-11-01 2017-11-20 0000895051 us-gaap:PreferredStockMember 2018-03-31 0000895051 us-gaap:CommonStockMember 2018-03-31 0000895051 us-gaap:TreasuryStockMember 2018-03-31 0000895051 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000895051 us-gaap:RetainedEarningsMember 2018-03-31 0000895051 us-gaap:PreferredStockMember 2017-12-31 0000895051 us-gaap:CommonStockMember 2017-12-31 0000895051 us-gaap:TreasuryStockMember 2017-12-31 0000895051 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000895051 us-gaap:RetainedEarningsMember 2017-12-31 0000895051 us-gaap:EmployeeStockOptionMember 2017-12-31 0000895051 casi:AbbreviatedNewDrugApplicationsMember 2018-01-01 2018-03-31 0000895051 casi:AccountingStandardsUpdate201701Member 2018-01-01 2018-03-31 0000895051 casi:ActivePharmaceuticalIngredientMember 2018-01-01 2018-03-31 0000895051 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0000895051 us-gaap:WarrantMember 2018-01-01 2018-03-31 0000895051 casi:AbbreviatedNewDrugApplicationsMember 2018-03-31 0000895051 casi:AbbreviatedNewDrugApplicationsMember 2018-01-01 2018-03-31 0000895051 us-gaap:PublicUtilitiesInventoryRawMaterialsMember 2018-03-31 0000895051 us-gaap:SubsequentEventMember casi:CurrentStockholdersMember 2018-04-30 0000895051 casi:SecuritiesPurchaseAgreementsMember us-gaap:SubsequentEventMember 2018-04-30 0000895051 casi:SecuritiesPurchaseAgreementsMember us-gaap:SubsequentEventMember 2018-03-02 2018-04-30 0000895051 us-gaap:PrivatePlacementMember 2018-03-31 0000895051 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000895051 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0000895051 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0000895051 us-gaap:SubsequentEventMember 2018-04-01 2018-04-30 0000895051 us-gaap:WarrantMember 2017-12-31 0000895051 us-gaap:WarrantMember 2018-03-31 0000895051 casi:InvestorsMember 2018-03-01 2018-03-31 0000895051 us-gaap:InvestorMember us-gaap:SubsequentEventMember 2018-03-02 2018-04-30 0000895051 us-gaap:InvestorMember 2018-03-01 2018-03-31 0000895051 us-gaap:SubsequentEventMember casi:CurrentStockholdersMember 2018-03-02 2018-04-30 0000895051 us-gaap:PrivatePlacementMember us-gaap:SubsequentEventMember 2018-03-02 2018-04-30 0000895051 us-gaap:InvestorMember us-gaap:SubsequentEventMember 2018-04-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 10-Q false 2018-03-31 2018 Q1 CASI Pharmaceuticals, Inc. 0000895051 --12-31 Smaller Reporting Company CASI 86145298

43489935

876026

322493

52085651

43812428

1200830

1046514

70694

242023

71162019

45100965

1581931

529389427

498577372

8034244

-455060627

-452702029

67619021

38540114

71162019

45100965

3542998

6560851

1498754

1498931

2087770

462136

745961

2044067

5062097

797214

699015

49887600

2228366

1697232

1049287

1303122

644163

-0.05

-0.03

29790217

91865

29698352

9186452

98022

572

97450

57214

211685

260040

-3590910

-1700182

65822

18528

260040

156250

-52886

17932

-522274

55371

-287672

-51245

-5402871

-1530467

155144

33509

-19327100

-33509

6397665

-1563976

27092928

25528952

177

1869

6874

211685

30650214

-2228366

29790217 0

98022

29300000

23800000

20900000

1869

0.005

136000

1500000

3.69

3.24 25000000

143248

475000

2478048

11902287

0.86

7.37

1000000

4000000

67198

89052

103767

156273

0.003 0.004

0.7951

0.0263

0.8107

0.0203

391000

57214

16814

8630758

3.7

1.71

3.05

1.58

1.04

2.61

P2Y P5Y

1322025

17804844

527251

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.5in"> <div><b>1.</b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b>Basis of Presentation</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The accompanying condensed consolidated financial statements include the accounts of CASI Pharmaceuticals, Inc. and its subsidiaries (“CASI” or “the Company”), Miikana Therapeutics, Inc. (“Miikana”) and CASI Pharmaceuticals (Beijing) Co., Ltd. (“CASI China”). The Company previously operated under a different name prior to restructuring its business in 2012 in connection with an investment led by one of the Company’s largest stockholders. CASI China is a non-stock Chinese entity with <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% of its interest owned by CASI. CASI China received approval for a business license from the Beijing Industry and Commercial Administration in August 2012 and has operating facilities in Beijing. All inter-company balances and transactions have been eliminated in consolidation.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, such condensed consolidated financial statements do not include all of the information and disclosures required by U.S. generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. The accompanying December 31, 2017 financial information was derived from the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. Operating results for the three month period ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018 or any other future period. For further information, refer to the Company’s audited consolidated financial statements and footnotes thereto included in its Form 10-K for the year ended December 31, 2017.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><u>Liquidity Risks and Management’s Plans</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Since inception, the Company has incurred significant losses from operations and has incurred an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">455.1</font> million. The Company restructured its business in 2012 in connection with an investment led by one of the Company’s largest stockholders, followed by implementation of a name change to reflect its core mission and business strategy. The Company expects to continue to incur operating losses for the foreseeable future due to, among other factors, its continuing clinical activities. In March 2018, the Company entered into securities purchase agreements pursuant to which the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,432,091</font> shares of its common stock with accompanying warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,172,832</font> shares of its common stock in a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50</font> million private placement (the “2018 Financing”). The Company received gross proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">29.3</font> million in March 2018 and received additional gross proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20.7</font> million in April 2018. The 2018 Financing closing included an investment from ETP Global Fund, L.P., a healthcare investment fund. The managing member of Emerging Technology Partners, LLC, which is the general partner of ETP Global Fund, L.P., is also the Executive Chairman of the Company. The 2018 Financing also included an investment from IDG-Accel China Growth Fund III L.P. (“IDG-Accel Growth”) and IDG-Accel China III Investors L.P. (“IDG-Accel Investors”). A director and shareholder of IDG-Accel China Growth Fund GP III Associates Ltd., which is the ultimate general partner of IDG-Accel Growth and IDG-Accel Investors, is also a member of the Company’s Board of Directors. In October 2017, the Company entered into securities purchase agreements for an approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">23.8</font> million strategic financing. The Company held its initial closing on October 17, 2017, a second closing on October 23, 2017 and a final closing on November 20, 2017 and received approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">23.4</font> million in net proceeds, (collectively, the “2017 Closings”). Net proceeds from the 2018 Financing and the 2017 Closings are being used to prepare for the anticipated launch of the Company’s first commercial product in China, to support the Company’s business development activities, to advance the development of the Company’s pipeline, to support its marketing and commercial planning activities, and for other general corporate purposes.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> As a result of the 2018 Financing and 2017 Closings, the Company believes that it has sufficient resources to fund its operations at least through May 15, 2019. As of March 31, 2018, approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20.9</font> million of the Company’s cash balance was held by CASI China. The Company intends to continue to exercise tight controls over operating expenditures and will continue to pursue opportunities, as required, to raise additional capital and will also actively pursue non- or less-dilutive capital raising arrangements in China to support the Company’s dual-country approach to drug development.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

1.00

5000000

23400000

0.01

170000000

79721421

69901625

79545

686998

6729

142

177

3687352

1693450

89713

71215000

60196574

527251

-3063659

-1700182

797214

-8034244

529389427

-455060627

79641876

699015

-8034244

498577372

-452702029

69822080

1232312

5500000

3200000

973660 0 5762 0 967898 0 576130

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.5in"> <div style="CLEAR:both;CLEAR: both"><strong>12.</strong></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><strong>Stock-Based Compensation and Warrants</strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company has adopted incentive and nonqualified stock option plans for executive, scientific and administrative personnel of the Company as well as outside directors and consultants. As of March 31, 2018, there are <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11,902,287</font> shares issuable under options previously granted and currently outstanding, with exercise prices ranging from $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.86</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.37</font>. Options granted under the plans generally vest over periods varying from immediately to one to three years, are not transferable and generally expire ten years from the date of grant. As of March 31, 2018, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,478,048</font> shares remained available for grant under the Company’s 2011 Long-Term Incentive Plan. On March 13, 2018, upon the recommendation of the Compensation Committee of the Board of Directors (the “Board”), the Board approved a grant of stock options to the Company’s Executive Chairman exercisable for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1</font> million shares of common stock that will vest and become exercisable on the first anniversary date of the grant. In addition, the Board approved the grant of a performance-based option covering <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4</font> million shares of common stock that will vest if, within 18 months of the date of grant, specific operational and strategic milestones are achieved. Both grants are conditioned upon stockholder approval at the 2018 Annual Meeting of Stockholders.</div>  </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company records compensation expense associated with stock options and other equity-based compensation in accordance with provisions of authoritative guidance. Compensation costs are recognized over the requisite service period, which is generally the option vesting term of up to three years. Awards with performance conditions will be expensed if it is probable that the performance condition will be achieved. There was no expense recorded for share awards with performance conditions during the three months ended March 31, 2018 and 2017.</div>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Company’s net loss for the three months ended March 31, 2018 and 2017 includes $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">260,040</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">156,250</font>, respectively, of non-cash compensation expense related to the Company’s share-based compensation awards. The compensation expense related to the Company’s share-based compensation arrangements is recorded as components of general and administrative expense and research and development expense, as follows:</div>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div style="CLEAR:both;CLEAR: both"> Three Months period ended<br/> March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">103,767</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">67,198</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">156,273</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">89,052</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Share-based compensation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">260,040</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">156,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Net share-based compensation expense, per common share:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Basic and diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">0.004</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">0.003</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company uses the Black-Scholes-Merton valuation model to estimate the fair value of service based and performance based stock options granted to employees. Option valuation models, including Black-Scholes-Merton, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant date fair value of an award.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> Following are the weighted-average assumptions used in valuing the stock options granted to employees during the three-month periods ended March 31, 2018 and 2017:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="28%" colspan="5"> <div style="CLEAR:both;CLEAR: both"> Three Month Period ended March 31,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 2px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 2px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="2%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 2px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div style="CLEAR:both;CLEAR: both">Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">79.51</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 2px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">81.07</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 2px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div style="CLEAR:both;CLEAR: both">Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">2.63</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 2px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">2.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 2px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div style="CLEAR:both;CLEAR: both">Expected term of option</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">6.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 2px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">5.81</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 2px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">years</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div style="CLEAR:both;CLEAR: both">Expected dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 2px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 2px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">% <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The weighted average fair value of stock options granted during the three-month periods ended March 31, 2018 and 2017 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.61</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.04</font>, respectively.</div>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of the Company's stock option plans and of changes in options outstanding under the plans during the three-month period ended March 31, 2018 is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number of Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted Average<br/> Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Outstanding at January 1, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">11,585,315</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1.42</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">(57,214)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1.71</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">391,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">3.70</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">(16,814)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">3.05</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Outstanding at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">11,902,287</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Exercisable at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">8,630,758</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1.58</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Cash received from option exercises under all share-based payment arrangements for the three months ended March 31, 2018 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">98,022</font>. There were no option exercises during the three months ended March 31, 2017.</div>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><u>Warrants</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Warrants issued generally expire after <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2</font>-<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font> years from the date of issuance. Stock warrant activity is as follows:</div>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> Number of Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted Average<br/> Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Outstanding at January 1, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">6,264,016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">2.23</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">3,617,279</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">3.69</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">(576,130)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1.69</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Outstanding at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">9,305,165</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">2.83</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Exercisable at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">4,049,380</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1.69</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Cash received from warrants exercised during the three months ended March 31, 2018 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">973,660</font>. There were no warrants exercised during the three months ended March 31, 2017.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

P6Y3M22D

P5Y9M22D

11585315

11902287

1.42

1.50

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company’s net loss for the three months ended March 31, 2018 and 2017 includes $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">260,040</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">156,250</font>, respectively, of non-cash compensation expense related to the Company’s share-based compensation awards. The compensation expense related to the Company’s share-based compensation arrangements is recorded as components of general and administrative expense and research and development expense, as follows:</div>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div style="CLEAR:both;CLEAR: both"> Three Months period ended<br/> March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">103,767</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">67,198</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">156,273</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">89,052</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Share-based compensation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">260,040</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">156,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Net share-based compensation expense, per common share:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Basic and diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">0.004</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">0.003</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

250141

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">A summary of the Company's stock option plans and of changes in options outstanding under the plans during the three-month period ended March 31, 2018 is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number of Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted Average<br/> Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Outstanding at January 1, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">11,585,315</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1.42</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">(57,214)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1.71</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">391,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">3.70</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">(16,814)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">3.05</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Outstanding at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">11,902,287</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Exercisable at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">8,630,758</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1.58</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

89713

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Warrants issued generally expire after <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2</font>-<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font> years from the date of issuance. Stock warrant activity is as follows:</div>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> Number of Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted Average<br/> Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Outstanding at January 1, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">6,264,016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">2.23</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">3,617,279</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">3.69</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">(576,130)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1.69</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Outstanding at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">9,305,165</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">2.83</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Exercisable at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">4,049,380</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1.69</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

19171956

477422

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.5in"> <div><strong>2.</strong></div> </td> <td style="TEXT-ALIGN: justify"> <div><strong>Acquisition of Abbreviated New Drug Applications</strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On January 26, 2018, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Sandoz, Inc. (“Sandoz”). Pursuant to the Asset Purchase Agreement, the Company acquired a portfolio of 29 abbreviated new drug applications (“ANDAs”), including 25 ANDAs approved by the U.S. Food and Drug Administration (“FDA”) and four pipeline ANDAs that are pending FDA approval, limited quantities of certain active pharmaceutical ingredient (“API”), and certain manufacturing and other information related to the products (collectively, the ANDAs, API and other information is referred to as the “Acquired Assets”). To facilitate the sale and transition, the parties also entered into several limited term ancillary arrangements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Acquired Assets enhance the Company’s strategic focus to build a robust pipeline and commercialize quality drug candidates in China. The Company intends to select and commercialize certain products from the portfolio that have unique market and cost-effective manufacturing opportunities in China (and potentially in the U.S.).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The total purchase price for the Acquired Assets was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18.0</font> million in cash. The Company accounted for the purchase of the Acquired Assets as an asset acquisition (consisting of a concentrated group of similar identifiable assets, including ANDAs and API) following the guidance contain in Accounting Standards Update (“ASU”) 2017-01. The total purchase price, along with approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.2</font> million of transaction expenses, was allocated to the Acquired Assets based on their relative fair values, as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 40%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>ANDAs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,608,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>API</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>564,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Total value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>19,172,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Of the total value allocated to the ANDAs, approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">553,000</font> was immediately expensed as acquired in-process research and development since the underlying ANDAs have not been approved by the FDA, and of the total value allocated to the API, approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">134,000</font> was immediately expensed as acquired in-process research and development since the Company does not intend to use all of the API. The allocated cost of the capitalized ANDAs will be amortized over their estimated useful lives of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13</font> years. The capitalized API will be expensed in the period it is used or if its value is otherwise impaired.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The fair values of certain acquired ANDAs were estimated using the discounted cash flow method (an income approach), which involves the use of Level 3 inputs such as estimates for projected sales, expenses, and cash flows, estimates of total addressable markets and market penetration rates, future sales growth and inflation rates, expected income and value-added tax rates, and a required rate of return adjusted for both industry and Company-specific risks, among other inputs. The fair values of the remaining ANDAs were estimated using a multiple of values method (an income approach), which involved using Level 3 inputs such as estimated addressable markets and market penetration rates. The fair value of the API was estimated using Level 2 inputs, such as quoted market prices for similar API from various suppliers or other sources. The ANDAs will be tested for impairment when events or circumstances indicate that the carrying value of the asset may not be recoverable; no such triggering events were identified during the period from the date of acquisition to March 31, 2018.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

334000

561900

140500

973660

18608000 1200000

P13Y

553000

134000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.5in"> <div><strong>3.</strong></div> </td> <td style="TEXT-ALIGN: justify"> <div><strong>Intangible Assets</strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Intangible assets were acquired as part of the 2018 asset acquisition from Sandoz and include ANDAs for a total of 25 previously marketed generic products. These intangible assets were originally recorded at relative fair values based on the purchase price for the asset acquisition and are stated net of accumulated amortization.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The ANDAs are being amortized over their estimated useful lives of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13</font> years, using the straight-line method. Management reviews finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, in a manner similar to that for property and equipment. No impairment losses related to intangible assets were recognized in the three months ended March 31, 2018.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">As discussed in Note 2, in January 2018, the Company purchased the Acquired Assets from Sandoz for a total purchase price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18.0</font> million. The total purchase price, along with transaction expenses of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.2</font> million, was allocated to the ANDAs and API acquired based on their relative fair values.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> Net finite-lived intangible assets at March 31, 2018 consists of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="26%"> <div>Asset</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="2"> <div>Gross Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%" colspan="2"> <div>Accumulated Amortization</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%"> <div>Estimated useful lives</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="26%"> <div>ANDAs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="26%"> <div>18,054,985</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="28%"> <div>(250,141)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div>13 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Expected future amortization expense is as follows for the years ending December 31:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 65%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2018 (remaining nine months)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,041,634</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,388,845</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,388,845</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2021</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,388,845</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,388,845</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2023 and thereafter</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>11,207,830</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Expected future amortization expense is as follows for the years ending December 31:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 65%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2018 (remaining nine months)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,041,634</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,388,845</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,388,845</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2021</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,388,845</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,388,845</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2023 and thereafter</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>11,207,830</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

11902287

9305165

18054985

-250141

P13Y

430000

18000000

2555553

1041634

1388845

11207830

15062000 2.44

P5Y

0.754

0.0269

50000000

527251

20700000

3617279

576130

4049380 3.69 0 1.69 1.69 6264016 9305165 2.23 2.83 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 40%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>ANDAs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,608,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>API</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>564,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Total value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>19,172,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

527251

15432091

9043204

6388887

50000000

564000 19172000 24500000 6172832

6172832

3617279

EX-101.SCH 7 casi-20180331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Condensed Consolidated Balance Sheets [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Condensed Consolidated Statement of Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 106 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Acquisition of Abbreviated New Drug Applications link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Intangible Assets link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Foreign Currency Translation link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Investments link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Research and Development link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - License Arrangements link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Note Payable link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Stockholders’ Equity link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Net Loss Per Share link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Stock-Based Compensation and Warrants link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - New Accounting Pronouncements link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Commitments link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Acquisition of Abbreviated New Drug Applications (Tables) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Intangible Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Stock-Based Compensation and Warrants (Tables) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Basis of Presentation (Details Textual) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Acquisition of Abbreviated New Drug Applications (Details) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Acquisition of Abbreviated New Drug Applications (Details Textual) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Intangible Assets (Details) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Intangible Assets (Details 1) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - Intangible Assets (Details Textual) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - Investments (Details Textual) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - Inventories (Details Textual) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - Note Payable (Details Textual) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - Stockholders’ Equity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - Net Loss Per Share (Details Textual) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - Stock-Based Compensation and Warrants (Details) link:presentationLink link:definitionLink link:calculationLink 138 - Disclosure - Stock-Based Compensation and Warrants (Details 1) link:presentationLink link:definitionLink link:calculationLink 139 - Disclosure - Stock-Based Compensation and Warrants (Details 2) link:presentationLink link:definitionLink link:calculationLink 140 - Disclosure - Stock-Based Compensation and Warrants (Details 3) link:presentationLink link:definitionLink link:calculationLink 141 - Disclosure - Stock-Based Compensation and Warrants (Details Textual) link:presentationLink link:definitionLink link:calculationLink 142 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:definitionLink link:calculationLink 143 - Disclosure - Commitments (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 casi-20180331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 casi-20180331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 casi-20180331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Trading Symbol Entity Common Stock, Shares Outstanding Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Tax Disclosure [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule Of Employee Service Share-Based Compensation, Allocation Of Recognized Period Costs [Table Text Block] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule Of Share-Based Compensation, Stock Options, Activity [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Shedule of Description of Business and Basis of Presentation [Table] Legal Entity [Axis] Entity [Domain] Scenario [Axis] Scenario, Unspecified [Domain] Class of Stock [Domain] Stock Issued [Axis] Retained Earnings (Accumulated Deficit), Total Accumulated deficit Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Income Statement Location [Axis] Income Statement Location [Domain] Research and Development Expense [Member] General and Administrative Expense [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation, Total Stock-based compensation expense Net Share Based Compensation Expense Per Common Share Abstract Net share-based compensation expense, per common share: Share Based Compensation Expenses Basic and Diluted Per Share Basic and diluted (in dollars per share) The amount of share-based compensation expenses per each share of common stock or unit outstanding during the reporting period. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term of option Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Type of Deferred Compensation [Axis] Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain] Employee Stock Option [Member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance Outstanding - Number of Options, Beginning Balance Outstanding - Number of Options, Ending Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period Exercised - Number of Options Issuance of common stock for options exercised (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross Granted - Number of Options Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Expirations In Period Expired - Number of Options Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period Forfeited - Number of Options Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number Exercisable - Number of Options Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding - Weighted Average Exercise Price, Beginning balance Outstanding - Weighted Average Exercise Price, Ending Balance Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised - Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted - Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Expired - Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited - Weighted Average Exercise Price Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable - Weighted Average Exercise Price Plan Name [Axis] Plan Name [Domain] Long Term Incentive Plan2011 [Member] Range [Axis] Range [Domain] Maximum [Member] Minimum [Member] Title of Individual [Axis] Relationship to Entity [Domain] Equity Components [Axis] Equity Component [Domain] Award Type [Axis] Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Proceeds from Stock Options Exercised Proceeds from exercise of stock options Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Income Tax Contingency [Table] Equity Award [Domain] Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name [Domain] Unrecognized Tax Benefits, Beginning Balance Unrecognized Tax Benefits Unrecognized tax benefits balance at January 1 Unrecognized tax benefits balance at December 31 Statement Of Financial Position [Abstract] Statement [Table] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Short-term Investments Investments, at market Property, Plant and Equipment, Net, Total Property and equipment, net Property, Plant and Equipment, Net Other Assets, Noncurrent Other assets Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accounts Payable, Related Parties, Current Payable to related parties Notes Payable, Noncurrent Note payable, net of discount Accrued Liabilities, Current Accrued liabilities Preferred Stock, Value, Issued Preferred stock, $1.00 par value: 5,000,000 shares authorized and 0 shares issued and outstanding at March 31, 2018 and December 31, 2017 Common Stock, Value, Issued Common stock, $.01 par value: 170,0000,000 shares authorized at March 31, 2018 and December 31, 2017; 79,721,421 shares and 69,901,625 shares issued at March 31, 2018 and December 31, 2017, respectively Additional Paid in Capital, Total Additional paid-in capital Treasury Stock, Value Treasury stock, at cost: 79,545 shares held at March 31, 2018 and December 31, 2017 Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Liabilities Total liabilities Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Income Statement [Abstract] Revenues [Abstract] Revenues: Costs and Expenses [Abstract] Costs and expenses Research and Development Expense, Total Research and development General and Administrative Expense, Total General and administrative Interest Income (Expense), Net, Total Interest income, net Other Income Other income Increase (Decrease) in Derivative Liabilities Changes in fair value of contingent rights Change in fair value of contingent rights Net Income (Loss) Attributable to Parent, Total Net loss Net loss Statement Of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization, Nonproduction, Total Depreciation and amortization Amortization of Intangible Assets Amortization of intangible assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Prepaid expenses and other Increase (Decrease) in Accounts Payable, Total Accounts payable Increase (Decrease) In Accounts Payable, Related Parties Payable to related party Increase (Decrease) in Accrued Liabilities, Total Accrued liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES Payments to Acquire Property, Plant, and Equipment, Total Purchases of property and equipment Payments to Acquire Intangible Assets Acquisition of Abbreviated New Drug Applications and related items Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES Effect of Exchange Rate on Cash and Cash Equivalents Effect of exchange rate changes on cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease), Total Net increase (decrease) in cash and cash equivalents Basis Of Accounting [Text Block] Basis of Accounting [Text Block] Commitments and Contingencies Commitments and contingencies New Accounting Pronouncements and Changes in Accounting Principles [Abstract] New Accounting Pronouncements and Changes in Accounting Principles [Text Block] License Arrangements Disclosure [Abstract] License Arrangements Disclosure [Text Block] The entire disclosure for license arrangements. Debt Disclosure [Abstract] Debt Disclosure [Text Block] Schedule of Notes payable [Table] Related Party [Axis] Related Party [Domain] Subsequent Event Type [Axis] Spectrum Pharmaceuticals [Member] Amortization of Debt Discount (Premium) Debt Instrument, Interest Rate, Stated Percentage Stockholders Equity Attributable To Parent [Abstract] Stockholders’ equity: Liabilities and Equity, Total Total liabilities and stockholders’ equity Research and Development in Process Acquired in-process research and development Earnings Per Share, Basic and Diluted, Total Net loss per share (basic and diluted) Unrealized Gain (Loss) on Investments Unrealized gain on equity investment Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Percentage Of Ownership Interest In Non Stock Subsidiary Percentage of ownership interest held by the parent entity in the non stock subsidiary. Prepaid Expense and Other Assets, Current Prepaid expenses and other Treasury Stock, Shares Treasury stock, shares held Costs and Expenses, Total Costs and expenses Revenue, Net Product sales Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Preferred Stock [Member] Common Stock [Member] Treasury Stock [Member] Additional Paid-in Capital [Member] Stockholders' Equity Attributable to Parent Balance Total stockholders’ equity Balance Shares, Outstanding Balance (in Shares) Balance (in shares) Cumulative Effect on Retained Earnings, Net of Tax Cumulative effect adjustment due to the adoption of ASU 2016-01 Stock Issued During Period, Value, Other Issuance of common stock and warrants pursuant to financing agreements Stock Issued During Period, Shares, Other Issuance of common stock and warrants pursuant to financing agreements (in shares) Stock Issued During Period Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock for options exercised Stock Issued During Period Value Warrants Exercised1 Issuance of common stock from exercise of warrants Value of stock issued as a result of the exercise of stock options. Share-based Compensation Arrangement by Share-based Payment Award, Warrants, Exercises in Period Issuance of common stock from exercise of warrants (in Shares) Number of warrants exercised during the current period. AOCI Attributable to Parent [Member] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Purchase Obligation To purchase materials Purchase obligation to purchase materials It represents the purchase obligation to purchase materials. Geographical [Axis] Schedule Of Warrant Activity [Table Text Block] Tabular disclosure related to the share based warrant activity. Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-cash financing activity: Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Expire Terms Represents the expire date of stock other than option granted under share based compensation Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Stock issuance costs Stock Issued [Domain] Securities Purchase Agreements [Abstract] Class of Warrant or Right, Exercise Price of Warrants or Rights Class of Warrant or Right, Exercise Price of Warrants or Rights Fair Value Of Warrant Issued Fair Value Of Warrant Issued Fair value of warrant issued as on date. Fair Value Assumptions Fair Value Fair Value Assumptions Fair Value Reflects the fair value of warrants issued. Fair Value Assumptions, Expected Term Fair Value Assumptions, Expected Term Fair Value Assumptions, Risk Free Interest Rate Fair Value Assumptions, Risk Free Interest Rate Fair Value Assumptions, Expected Volatility Rate Fair Value Assumptions, Expected Volatility Rate Cash Flow, Noncash Investing Activities Disclosure [Abstract] Non-cash investing activity: EX-101.PRE 11 casi-20180331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2018	May 08, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1
Entity Registrant Name	CASI Pharmaceuticals, Inc.
Entity Central Index Key	0000895051
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	CASI
Entity Common Stock, Shares Outstanding		86,145,298

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 49,887,600	$ 43,489,935
Investments, at market	1,322,025	0
Prepaid expenses and other	876,026	322,493
Total current assets	52,085,651	43,812,428
Property and equipment, net	1,200,830	1,046,514
Other assets	70,694	242,023
Intangible assets, net	17,804,844	0
Total assets	71,162,019	45,100,965
Current liabilities:
Accounts payable	1,581,931	2,087,770
Payable to related parties	0	2,228,366
Accrued liabilities	462,136	745,961
Total current liabilities	2,044,067	5,062,097
Note payable, net of discount	1,498,931	1,498,754
Total liabilities	3,542,998	6,560,851
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $1.00 par value: 5,000,000 shares authorized and 0 shares issued and outstanding at March 31, 2018 and December 31, 2017	0	0
Common stock, $.01 par value: 170,0000,000 shares authorized at March 31, 2018 and December 31, 2017; 79,721,421 shares and 69,901,625 shares issued at March 31, 2018 and December 31, 2017, respectively	797,214	699,015
Additional paid-in capital	529,389,427	498,577,372
Treasury stock, at cost: 79,545 shares held at March 31, 2018 and December 31, 2017	(8,034,244)	(8,034,244)
Accumulated other comprehensive income	527,251	0
Accumulated deficit	(455,060,627)	(452,702,029)
Total stockholders’ equity	67,619,021	38,540,114
Total liabilities and stockholders’ equity	$ 71,162,019	$ 45,100,965

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets [Parenthetical] - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Preferred Stock, Par or Stated Value Per Share	$ 1.00	$ 1.00
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	170,000,000	170,000,000
Common stock, shares issued	79,721,421	69,901,625
Treasury stock, shares held	79,545	79,545

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenues:
Product sales	$ 0	$ 0
Costs and expenses
Research and development	1,697,232	1,049,287
General and administrative	1,303,122	644,163
Acquired in-process research and development	686,998	0
Costs and expenses	3,687,352	1,693,450
Interest income, net	(6,729)	(142)
Other income	(89,713)	0
Changes in fair value of contingent rights	0	6,874
Net loss	$ (3,590,910)	$ (1,700,182)
Net loss per share (basic and diluted)	$ (0.05)	$ (0.03)
Weight average number of shares outstanding (basic and diluted)	71,215,000	60,196,574
Comprehensive loss:
Net loss	$ (3,590,910)	$ (1,700,182)
Foreign currency translation adjustment	527,251	0
Total comprehensive loss	$ (3,063,659)	$ (1,700,182)

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Stockholders' Equity - 3 months ended Mar. 31, 2018 - USD ($)	Total	Preferred Stock [Member]	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2017	$ 38,540,114	$ 0	$ 699,015	$ (8,034,244)	$ 498,577,372	$ 0	$ (452,702,029)
Balance (in Shares) at Dec. 31, 2017		0	69,822,080
Cumulative effect adjustment due to the adoption of ASU 2016-01	1,232,312	$ 0	$ 0	0	0	0	1,232,312
Issuance of common stock and warrants pursuant to financing agreements	29,790,217	$ 0	$ 91,865	0	29,698,352	0	0
Issuance of common stock and warrants pursuant to financing agreements (in shares)		0	9,186,452
Issuance of common stock for options exercised	98,022	$ 0	$ 572	0	97,450	0	0
Issuance of common stock for options exercised (in shares)		0	57,214
Issuance of common stock from exercise of warrants	973,660	$ 0	$ 5,762	0	967,898	0	0
Issuance of common stock from exercise of warrants (in Shares)		0	576,130
Stock issuance costs	(211,685)	$ 0	$ 0	0	(211,685)	0	0
Stock-based compensation expense	260,040	0	0	0	260,040	0	0
Foreign currency translation adjustment	527,251	0	0	0	0	527,251	0
Net loss	(3,590,910)	0	0	0	0	0	(3,590,910)
Balance at Mar. 31, 2018	$ 67,619,021	$ 0	$ 797,214	$ (8,034,244)	$ 529,389,427	$ 527,251	$ (455,060,627)
Balance (in shares) at Mar. 31, 2018		0	79,641,876

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (3,590,910)	$ (1,700,182)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	65,822	18,528
Amortization of intangible assets	250,141	0
Stock-based compensation expense	260,040	156,250
Acquired in-process research and development	686,998	0
Unrealized gain on equity investment	(89,713)	0
Non-cash interest	177	1,869
Change in fair value of contingent rights	0	6,874
Changes in operating assets and liabilities:
Prepaid expenses and other	52,886	(17,932)
Accounts payable	(522,274)	55,371
Payable to related party	(2,228,366)	0
Accrued liabilities	(287,672)	(51,245)
Net cash used in operating activities	(5,402,871)	(1,530,467)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(155,144)	(33,509)
Acquisition of Abbreviated New Drug Applications and related items	(19,171,956)	0
Net cash used in investing activities	(19,327,100)	(33,509)
CASH FLOWS FROM FINANCING ACTIVITIES
Stock issuance costs	(211,685)	0
Proceeds from sale of common stock and warrants	29,790,217	0
Proceeds from exercise of stock options	98,022	0
Proceeds from exercise of stock warrants	973,660	0
Net cash provided by financing activities	30,650,214	0
Effect of exchange rate changes on cash and cash equivalents	477,422	0
Net increase (decrease) in cash and cash equivalents	6,397,665	(1,563,976)
Cash and cash equivalents at beginning of period	43,489,935	27,092,928
Cash and cash equivalents at end of period	$ 49,887,600	$ 25,528,952

XML 18 R7.htm IDEA: XBRL DOCUMENT

Basis of Presentation

3 Months Ended

Mar. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Accounting [Text Block]

1.	Basis of Presentation

Liquidity Risks and Management’s Plans

XML 19 R8.htm IDEA: XBRL DOCUMENT

Acquisition of Abbreviated New Drug Applications

3 Months Ended

Mar. 31, 2018

Acquisition of Abbreviated New Drug Applications [Abstract]

Acquisition of Abbreviated New Drug Applications [Text Block]

2.	Acquisition of Abbreviated New Drug Applications

ANDAs	$	18,608,000
API		564,000
Total value	$	19,172,000

XML 20 R9.htm IDEA: XBRL DOCUMENT

Intangible Assets

3 Months Ended

Mar. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets [Table Text Block]

3.	Intangible Assets

Asset		Gross Value			Accumulated Amortization			Estimated useful lives
ANDAs		$	18,054,985		$	(250,141)		13 years

Expected future amortization expense is as follows for the years ending December 31:

2018 (remaining nine months)	$	1,041,634
2019		1,388,845
2020		1,388,845
2021		1,388,845
2022		1,388,845
2023 and thereafter		11,207,830

XML 21 R10.htm IDEA: XBRL DOCUMENT

Foreign Currency Translation

3 Months Ended

Mar. 31, 2018

Foreign Currency [Abstract]

Foreign Currency Disclosure [Text Block]

4.	Foreign Currency Translation

XML 22 R11.htm IDEA: XBRL DOCUMENT

Investments

3 Months Ended

Mar. 31, 2018

Schedule of Investments [Abstract]

Investment Holdings, Schedule of Investments [Text Block]

5.	Investments

XML 23 R12.htm IDEA: XBRL DOCUMENT

Inventories

3 Months Ended

Mar. 31, 2018

Inventory Disclosure [Abstract]

Inventory Disclosure [Text Block]

6.	Inventories

XML 24 R13.htm IDEA: XBRL DOCUMENT

Research and Development

3 Months Ended

Mar. 31, 2018

Research and Development [Abstract]

Research, Development, and Computer Software Disclosure [Text Block]

7.	Research and Development

XML 25 R14.htm IDEA: XBRL DOCUMENT

License Arrangements

3 Months Ended

Mar. 31, 2018

License Arrangements Disclosure [Abstract]

License Arrangements Disclosure [Text Block]

8.	License Arrangements

EVOMELA^® (melphalan) for Injection (“EVOMELA”);

MARQIBO^® (vinCRIStine sulfate LIPOSOME injection) (“MARQIBO”); and

ZEVALIN^® (ibritumomab tiuxetan) (“ZEVALIN”).

XML 26 R15.htm IDEA: XBRL DOCUMENT

Note Payable

3 Months Ended

Mar. 31, 2018

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

9.	Note Payable

XML 27 R16.htm IDEA: XBRL DOCUMENT

Stockholders’ Equity

3 Months Ended

Mar. 31, 2018

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

10.

Stockholders’ Equity

Securities Purchase Agreements

Common Stock Sales Agreement

XML 28 R17.htm IDEA: XBRL DOCUMENT

Net Loss Per Share

3 Months Ended

Mar. 31, 2018

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

11.

Net Loss Per Share

XML 29 R18.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation and Warrants

3 Months Ended

Mar. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

12.

Stock-Based Compensation and Warrants

	Three Months period ended March 31,

	2018		2017
Research and development	$	103,767	$	67,198
General and administrative		156,273		89,052
Share-based compensation expense	$	260,040	$	156,250
Net share-based compensation expense, per common share:
Basic and diluted	$	0.004	$	0.003

	Three Month Period ended March 31,
	2018			2017
Expected volatility		79.51	%		81.07	%
Risk free interest rate		2.63	%		2.03	%
Expected term of option		6.31	years		5.81	years
Expected dividend yield		0.00	%		0.00	%

The weighted average fair value of stock options granted during the three-month periods ended March 31, 2018 and 2017 were $2.61 and $1.04, respectively.

A summary of the Company's stock option plans and of changes in options outstanding under the plans during the three-month period ended March 31, 2018 is as follows:

	Number of Options		Weighted Average Exercise Price
Outstanding at January 1, 2018		11,585,315	$	1.42
Exercised		(57,214)	$	1.71
Granted		391,000	$	3.70
Expired		-	$	-
Forfeited		(16,814)	$	3.05
Outstanding at March 31, 2018		11,902,287	$	1.50
Exercisable at March 31, 2018		8,630,758	$	1.58

Warrants

Warrants issued generally expire after 2-5 years from the date of issuance. Stock warrant activity is as follows:

	Number of Warrants		Weighted Average Exercise Price
Outstanding at January 1, 2018		6,264,016	$	2.23
Issued		3,617,279	$	3.69
Exercised		(576,130)	$	1.69
Expired		-	$	-
Outstanding at March 31, 2018		9,305,165	$	2.83
Exercisable at March 31, 2018		4,049,380	$	1.69

Cash received from warrants exercised during the three months ended March 31, 2018 was $973,660. There were no warrants exercised during the three months ended March 31, 2017.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Income Taxes

3 Months Ended

Mar. 31, 2018

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

13.

Income Taxes

XML 31 R20.htm IDEA: XBRL DOCUMENT

Related Party Transactions

3 Months Ended

Mar. 31, 2018

14.

Related Party Transactions

XML 32 R21.htm IDEA: XBRL DOCUMENT

New Accounting Pronouncements

3 Months Ended

Mar. 31, 2018

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

New Accounting Pronouncements and Changes in Accounting Principles [Text Block]

15.

New Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect and that may impact the Company’s consolidated financial statements.

There are no other recently issued accounting pronouncements that are expected to have a material effect on the Company's financial position, results of operations or cash flows.

XML 33 R22.htm IDEA: XBRL DOCUMENT

Commitments

3 Months Ended

Mar. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

16.

Commitments

In March 2018, the Company committed to a purchase obligation of EVOMELA^® from Spectrum for approximately $5.5 million.

XML 34 R23.htm IDEA: XBRL DOCUMENT

Acquisition of Abbreviated New Drug Applications (Tables)

3 Months Ended

Mar. 31, 2018

Acquisition of Abbreviated New Drug Applications [Abstract]

Schedule Of Finite Lived Intangible Assets and API Inventory [Table Text Block]

ANDAs	$	18,608,000
API		564,000
Total value	$	19,172,000

XML 35 R24.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Finite-lived Intangible Assets Amortization Expense [Table Text Block]

Net finite-lived intangible assets at March 31, 2018 consists of the following:

Asset		Gross Value			Accumulated Amortization			Estimated useful lives
ANDAs		$	18,054,985		$	(250,141)		13 years

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Expected future amortization expense is as follows for the years ending December 31:

2018 (remaining nine months)	$	1,041,634
2019		1,388,845
2020		1,388,845
2021		1,388,845
2022		1,388,845
2023 and thereafter		11,207,830

XML 36 R25.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation and Warrants (Tables)

3 Months Ended

Mar. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

	Three Months period ended March 31,

	2018		2017
Research and development	$	103,767	$	67,198
General and administrative		156,273		89,052
Share-based compensation expense	$	260,040	$	156,250
Net share-based compensation expense, per common share:
Basic and diluted	$	0.004	$	0.003

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Following are the weighted-average assumptions used in valuing the stock options granted to employees during the three-month periods ended March 31, 2018 and 2017:

	Three Month Period ended March 31,
	2018			2017
Expected volatility		79.51	%		81.07	%
Risk free interest rate		2.63	%		2.03	%
Expected term of option		6.31	years		5.81	years
Expected dividend yield		0.00	%		0.00	%

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of the Company's stock option plans and of changes in options outstanding under the plans during the three-month period ended March 31, 2018 is as follows:

	Number of Options		Weighted Average Exercise Price
Outstanding at January 1, 2018		11,585,315	$	1.42
Exercised		(57,214)	$	1.71
Granted		391,000	$	3.70
Expired		-	$	-
Forfeited		(16,814)	$	3.05
Outstanding at March 31, 2018		11,902,287	$	1.50
Exercisable at March 31, 2018		8,630,758	$	1.58

Schedule Of Warrant Activity [Table Text Block]

Warrants issued generally expire after 2-5 years from the date of issuance. Stock warrant activity is as follows:

	Number of Warrants		Weighted Average Exercise Price
Outstanding at January 1, 2018		6,264,016	$	2.23
Issued		3,617,279	$	3.69
Exercised		(576,130)	$	1.69
Expired		-	$	-
Outstanding at March 31, 2018		9,305,165	$	2.83
Exercisable at March 31, 2018		4,049,380	$	1.69

XML 37 R26.htm IDEA: XBRL DOCUMENT

Basis of Presentation (Details Textual) - USD ($)	1 Months Ended
Basis of Presentation (Details Textual) - USD ($)	Apr. 30, 2018	Mar. 31, 2018	Nov. 20, 2017	Oct. 17, 2017	Dec. 31, 2017
Description of Business and Basis of Presentation [Line Items]
Retained Earnings (Accumulated Deficit), Total		$ (455,060,627)			$ (452,702,029)
Percentage Of Ownership Interest In Non Stock Subsidiary		100.00%
Proceeds from Issuance of Common Stock		$ 29,300,000
Stock Issued During Period, Shares, New Issues		143,248
Net Proceeds From Issuance Of Common Stock		$ 475,000
Investors [Member]
Description of Business and Basis of Presentation [Line Items]
Stock Issued During Period, Shares, New Issues		15,432,091
Proceeds From Issuance Of Common Stock Gross				$ 23,800,000
Class of Warrant, Number of Warrants to Purchase Common Stock Issued During the Period		6,172,832
Second Closing [Member]
Description of Business and Basis of Presentation [Line Items]
Net Proceeds From Issuance Of Common Stock			$ 23,400,000
Private Placement [Member]
Description of Business and Basis of Presentation [Line Items]
Stock And Warrants Issued Value		$ 50,000,000
Subsequent Event [Member]
Description of Business and Basis of Presentation [Line Items]
Proceeds from Issuance of Common Stock	$ 20,700,000
CASI China [Member]
Description of Business and Basis of Presentation [Line Items]
Cash		$ 20,900,000

XML 38 R27.htm IDEA: XBRL DOCUMENT

Acquisition of Abbreviated New Drug Applications (Details)	3 Months Ended
	Mar. 31, 2018 USD ($)
Purchase Price For The Assets Acquired	$ 19,172,000
Abbreviated new drug applications [Member]
Purchase Price For Finite-lived Intangible Assets Acquired	18,608,000
Active pharmaceutical ingredient [Member]
Purchase Price For Raw Materials Inventory Acquired	$ 564,000

XML 39 R28.htm IDEA: XBRL DOCUMENT

Acquisition of Abbreviated New Drug Applications (Details Textual) - USD ($)	1 Months Ended	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2018	Mar. 31, 2017
Research and Development in Process		$ 686,998	$ 0
Finite-Lived Intangible Asset, Useful Life		13 years
Payments to Acquire Intangible Assets	$ 18,000,000	$ 19,171,956	$ 0
Abbreviated new drug applications [Member]
Research and Development in Process		553,000
Active pharmaceutical ingredient [Member]
Research and Development in Process		134,000
Accounting Standards Update 2017-01 [Member]
Asset Acquisition Transaction Costs		$ 1,200,000

XML 40 R29.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details)	3 Months Ended
Intangible Assets (Details)	Mar. 31, 2018 USD ($)
Estimated useful lives	13 years
Abbreviated new drug applications [Member]
Gross Value	$ 18,054,985
Accumulated Amortization	$ (250,141)
Estimated useful lives	13 years

XML 41 R30.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details 1)	Mar. 31, 2018 USD ($)
2018 (remaining nine months)	$ 1,041,634
2019	1,388,845
2020	1,388,845
2021	1,388,845
2022	1,388,845
2023 and thereafter	$ 11,207,830

XML 42 R31.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details Textual) - USD ($)	1 Months Ended	3 Months Ended
Intangible Assets (Details Textual) - USD ($)	Mar. 31, 2018	Mar. 31, 2018	Mar. 31, 2017
Finite-Lived Intangible Asset, Useful Life		13 years
Payments to Acquire Intangible Assets	$ 18,000,000	$ 19,171,956	$ 0
Accounting Standards Update 2017-01 [Member]
Asset Acquisition Transaction Costs		$ 1,200,000

XML 43 R32.htm IDEA: XBRL DOCUMENT

Investments (Details Textual) - USD ($)	3 Months Ended
Investments (Details Textual) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Short-term Investments	$ 1,322,025	$ 0
Cumulative Effect on Retained Earnings, Net of Tax	$ 1,232,312

XML 44 R33.htm IDEA: XBRL DOCUMENT

Inventories (Details Textual)	Mar. 31, 2018 USD ($)
Raw Materials [Member]
Inventory, Raw Materials, Net of Reserves	$ 430,000

XML 45 R34.htm IDEA: XBRL DOCUMENT

Note Payable (Details Textual) - USD ($)	3 Months Ended
Note Payable (Details Textual) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Notes Payable [Line Items]
Amortization of Debt Discount (Premium)	$ 177	$ 1,869
Spectrum Pharmaceuticals [Member]
Notes Payable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	0.50%
Debt Instrument Initial Discount Upon Issuance	$ 136,000
Debt Instrument, Face Amount	$ 1,500,000

XML 46 R35.htm IDEA: XBRL DOCUMENT

Stockholders’ Equity (Details Textual) - USD ($)	1 Months Ended		2 Months Ended
Stockholders’ Equity (Details Textual) - USD ($)	Apr. 30, 2018	Mar. 31, 2018	Apr. 30, 2018	Feb. 23, 2018
Proceeds from Issuance of Common Stock		$ 29,300,000
Net Proceeds From Issuance Of Common Stock		$ 475,000
Stock Issued During Period, Shares, New Issues		143,248
Price Per Share and Warrant		$ 3.24
Remaining Dollar Amount Available Under Sales Agreement		$ 24,500,000
Investors [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 3.69
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		3,617,279
Stock Issued During Period, Shares, New Issues		9,043,204
H.C. Wainwright Co., LLC [Member] \| Maximum [Member]
Aggregate Sales Price				$ 25,000,000
Subsequent Event [Member]
Proceeds from Issuance of Common Stock	$ 20,700,000
Subsequent Event [Member] \| Investors [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	6,172,832		6,172,832
Stock Issued During Period, Shares, New Issues			15,432,091
Subsequent Event [Member] \| Current Stockholders [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,555,553		2,555,553
Stock Issued During Period, Shares, New Issues			6,388,887
Securities Purchase Agreements [Member] \| Subsequent Event [Member]
Fair Value Of Warrant Issued	$ 15,062,000		$ 15,062,000
Fair Value Assumptions Fair Value			$ 2.44
Fair Value Assumptions, Expected Term			5 years
Fair Value Assumptions, Risk Free Interest Rate			2.69%
Fair Value Assumptions, Expected Volatility Rate			75.40%
Private Placement [Member] \| Subsequent Event [Member]
Stock Issued During Period, Value, New Issues			$ 50,000,000

XML 47 R36.htm IDEA: XBRL DOCUMENT

Net Loss Per Share (Details Textual)	3 Months Ended
Net Loss Per Share (Details Textual)	Mar. 31, 2018 shares
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	11,902,287
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	9,305,165

XML 48 R37.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation and Warrants (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 260,040	$ 156,250
Net share-based compensation expense, per common share:
Basic and diluted (in dollars per share)	$ 0.004	$ 0.003
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 103,767	$ 67,198
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 156,273	$ 89,052

XML 49 R38.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation and Warrants (Details 1)	3 Months Ended
Stock-Based Compensation and Warrants (Details 1)	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	79.51%	81.07%
Risk free interest rate	2.63%	2.03%
Expected term of option	6 years 3 months 22 days	5 years 9 months 22 days
Expected dividend yield	0.00%	0.00%

XML 50 R39.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation and Warrants (Details 2) - Employee Stock Option [Member]	3 Months Ended
	Mar. 31, 2018 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding - Number of Options, Beginning Balance \| shares	11,585,315
Exercised - Number of Options \| shares	(57,214)
Granted - Number of Options \| shares	391,000
Expired - Number of Options \| shares	0
Forfeited - Number of Options \| shares	(16,814)
Outstanding - Number of Options, Ending Balance \| shares	11,902,287
Exercisable - Number of Options \| shares	8,630,758
Outstanding - Weighted Average Exercise Price, Beginning balance \| $ / shares	$ 1.42
Exercised - Weighted Average Exercise Price \| $ / shares	1.71
Granted - Weighted Average Exercise Price \| $ / shares	3.7
Expired - Weighted Average Exercise Price \| $ / shares	0
Forfeited - Weighted Average Exercise Price \| $ / shares	3.05
Outstanding - Weighted Average Exercise Price, Ending Balance \| $ / shares	1.50
Exercisable - Weighted Average Exercise Price \| $ / shares	$ 1.58

XML 51 R40.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation and Warrants (Details 3) - Warrant [Member]	3 Months Ended
	Mar. 31, 2018 $ / shares shares
Outstanding at Number of Warrants, Beginning Balance \| shares	6,264,016
Issued Number of Warrants \| shares	3,617,279
Exercised Number of Warrants \| shares	(576,130)
Expired Number of Warrants \| shares	0
Outstanding at Number of Warrants, Ending Balance \| shares	9,305,165
Exercisable Number of Warrants \| shares	4,049,380
Outstanding Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 2.23
Issued Weighted Average Exercise Price \| $ / shares	3.69
Exercised Weighted Average Exercise Price \| $ / shares	1.69
Expired Weighted Average Exercise Price \| $ / shares	0
Outstanding Weighted Average Exercise Price, at Ending Balance \| $ / shares	2.83
Exercisable Weighted Average Exercise Price \| $ / shares	$ 1.69

XML 52 R41.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation and Warrants (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 13, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 2.61	$ 1.04
Share-based Compensation, Total	$ 260,040	$ 156,250
Proceeds from Stock Options Exercised	98,022	0
Proceeds from Warrant Exercises	$ 973,660	$ 0
Executive Chairman [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number			1,000,000
Executive Chairman [Member] \| Performance Based Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number			4,000,000
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Expire Terms	5 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Expire Terms	2 years
Long Term Incentive Plan2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	2,478,048
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	11,902,287
Long Term Incentive Plan2011 [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 7.37
Long Term Incentive Plan2011 [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 0.86

XML 53 R42.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Textual) $ in Millions	Dec. 31, 2017 USD ($)
Income Tax Contingency [Line Items]
Unrecognized Tax Benefits	$ 3.2

XML 54 R43.htm IDEA: XBRL DOCUMENT

Commitments (Details Textual) - USD ($)	3 Months Ended
Commitments (Details Textual) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Purchase obligation to purchase materials	$ 5,500,000
Operating Leases, Future Minimum Payments Receivable, Current		$ 334,000
Operating Leases, Future Minimum Payments Receivable, in Two Years		561,900
Operating Leases, Future Minimum Payments Receivable, in Three Years		561,900
Operating Leases, Future Minimum Payments Receivable, in Four Years		$ 140,500

EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 56 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * / var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 57 report.css IDEA: XBRL DOCUMENT / Updated 2009-11-04 / / v2.2.0.24 / / DefRef Styles / ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } / Report Styles / ..pl a, .pl a:visited { color: black; text-decoration: none; } / table / ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } / Top labels / ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; / word-wrap: break-word; / } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } / Header rows... / ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } / Calendars... / ..report .rc { background-color: #f0f0f0; } / Even rows... / ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } / Odd rows... / ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } / styles for footnote marker / ..report .fn { white-space: nowrap; } / styles for numeric types / ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } / styles for text types / ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 68 185 1 false 31 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.entremed.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.entremed.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 103 - Statement - Condensed Consolidated Balance Sheets [Parenthetical] Sheet http://www.entremed.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets [Parenthetical] Statements 3 false false R4.htm 104 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.entremed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 105 - Statement - Condensed Consolidated Statement of Stockholders' Equity Sheet http://www.entremed.com/role/CondensedConsolidatedStatementOfStockholdersEquity Condensed Consolidated Statement of Stockholders' Equity Statements 5 false false R6.htm 106 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.entremed.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 107 - Disclosure - Basis of Presentation Sheet http://www.entremed.com/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 108 - Disclosure - Acquisition of Abbreviated New Drug Applications Sheet http://www.entremed.com/role/AcquisitionOfAbbreviatedNewDrugApplications Acquisition of Abbreviated New Drug Applications Notes 8 false false R9.htm 109 - Disclosure - Intangible Assets Sheet http://www.entremed.com/role/IntangibleAssets Intangible Assets Notes 9 false false R10.htm 110 - Disclosure - Foreign Currency Translation Sheet http://www.entremed.com/role/ForeignCurrencyTranslation Foreign Currency Translation Notes 10 false false R11.htm 111 - Disclosure - Investments Sheet http://www.entremed.com/role/Investments Investments Notes 11 false false R12.htm 112 - Disclosure - Inventories Sheet http://www.entremed.com/role/Inventories Inventories Notes 12 false false R13.htm 113 - Disclosure - Research and Development Sheet http://www.entremed.com/role/ResearchAndDevelopment Research and Development Notes 13 false false R14.htm 114 - Disclosure - License Arrangements Sheet http://www.entremed.com/role/LicenseArrangements License Arrangements Notes 14 false false R15.htm 115 - Disclosure - Note Payable Sheet http://www.entremed.com/role/NotePayable Note Payable Notes 15 false false R16.htm 116 - Disclosure - Stockholders’ Equity Sheet http://www.entremed.com/role/StockholdersEquity Stockholders’ Equity Notes 16 false false R17.htm 117 - Disclosure - Net Loss Per Share Sheet http://www.entremed.com/role/NetLossPerShare Net Loss Per Share Notes 17 false false R18.htm 118 - Disclosure - Stock-Based Compensation and Warrants Sheet http://www.entremed.com/role/StockbasedCompensationAndWarrants Stock-Based Compensation and Warrants Notes 18 false false R19.htm 119 - Disclosure - Income Taxes Sheet http://www.entremed.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 120 - Disclosure - Related Party Transactions Sheet http://www.entremed.com/role/RelatedPartyTransactions Related Party Transactions Notes 20 false false R21.htm 121 - Disclosure - New Accounting Pronouncements Sheet http://www.entremed.com/role/NewAccountingPronouncements New Accounting Pronouncements Notes 21 false false R22.htm 122 - Disclosure - Commitments Sheet http://www.entremed.com/role/Commitments Commitments Notes 22 false false R23.htm 123 - Disclosure - Acquisition of Abbreviated New Drug Applications (Tables) Sheet http://www.entremed.com/role/AcquisitionOfAbbreviatedNewDrugApplicationsTables Acquisition of Abbreviated New Drug Applications (Tables) Tables http://www.entremed.com/role/AcquisitionOfAbbreviatedNewDrugApplications 23 false false R24.htm 124 - Disclosure - Intangible Assets (Tables) Sheet http://www.entremed.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://www.entremed.com/role/IntangibleAssets 24 false false R25.htm 125 - Disclosure - Stock-Based Compensation and Warrants (Tables) Sheet http://www.entremed.com/role/StockbasedCompensationAndWarrantsTables Stock-Based Compensation and Warrants (Tables) Tables http://www.entremed.com/role/StockbasedCompensationAndWarrants 25 false false R26.htm 126 - Disclosure - Basis of Presentation (Details Textual) Sheet http://www.entremed.com/role/BasisOfPresentationDetailsTextual Basis of Presentation (Details Textual) Details http://www.entremed.com/role/BasisOfPresentation 26 false false R27.htm 127 - Disclosure - Acquisition of Abbreviated New Drug Applications (Details) Sheet http://www.entremed.com/role/AcquisitionOfAbbreviatedNewDrugApplicationsDetails Acquisition of Abbreviated New Drug Applications (Details) Details http://www.entremed.com/role/AcquisitionOfAbbreviatedNewDrugApplicationsTables 27 false false R28.htm 128 - Disclosure - Acquisition of Abbreviated New Drug Applications (Details Textual) Sheet http://www.entremed.com/role/AcquisitionOfAbbreviatedNewDrugApplicationsDetailsTextual Acquisition of Abbreviated New Drug Applications (Details Textual) Details http://www.entremed.com/role/AcquisitionOfAbbreviatedNewDrugApplicationsTables 28 false false R29.htm 129 - Disclosure - Intangible Assets (Details) Sheet http://www.entremed.com/role/IntangibleAssetsDetails Intangible Assets (Details) Details http://www.entremed.com/role/IntangibleAssetsTables 29 false false R30.htm 130 - Disclosure - Intangible Assets (Details 1) Sheet http://www.entremed.com/role/IntangibleAssetsDetails1 Intangible Assets (Details 1) Details http://www.entremed.com/role/IntangibleAssetsTables 30 false false R31.htm 131 - Disclosure - Intangible Assets (Details Textual) Sheet http://www.entremed.com/role/IntangibleAssetsDetailsTextual Intangible Assets (Details Textual) Details http://www.entremed.com/role/IntangibleAssetsTables 31 false false R32.htm 132 - Disclosure - Investments (Details Textual) Sheet http://www.entremed.com/role/InvestmentsDetailsTextual Investments (Details Textual) Details http://www.entremed.com/role/Investments 32 false false R33.htm 133 - Disclosure - Inventories (Details Textual) Sheet http://www.entremed.com/role/InventoriesDetailsTextual Inventories (Details Textual) Details http://www.entremed.com/role/Inventories 33 false false R34.htm 134 - Disclosure - Note Payable (Details Textual) Sheet http://www.entremed.com/role/NotePayableDetailsTextual Note Payable (Details Textual) Details http://www.entremed.com/role/NotePayable 34 false false R35.htm 135 - Disclosure - Stockholders’ Equity (Details Textual) Sheet http://www.entremed.com/role/StockholdersEquityDetailsTextual Stockholders’ Equity (Details Textual) Details http://www.entremed.com/role/StockholdersEquity 35 false false R36.htm 136 - Disclosure - Net Loss Per Share (Details Textual) Sheet http://www.entremed.com/role/NetLossPerShareDetailsTextual Net Loss Per Share (Details Textual) Details http://www.entremed.com/role/NetLossPerShare 36 false false R37.htm 137 - Disclosure - Stock-Based Compensation and Warrants (Details) Sheet http://www.entremed.com/role/StockbasedCompensationAndWarrantsDetails Stock-Based Compensation and Warrants (Details) Details http://www.entremed.com/role/StockbasedCompensationAndWarrantsTables 37 false false R38.htm 138 - Disclosure - Stock-Based Compensation and Warrants (Details 1) Sheet http://www.entremed.com/role/StockbasedCompensationAndWarrantsDetails1 Stock-Based Compensation and Warrants (Details 1) Details http://www.entremed.com/role/StockbasedCompensationAndWarrantsTables 38 false false R39.htm 139 - Disclosure - Stock-Based Compensation and Warrants (Details 2) Sheet http://www.entremed.com/role/StockbasedCompensationAndWarrantsDetails2 Stock-Based Compensation and Warrants (Details 2) Details http://www.entremed.com/role/StockbasedCompensationAndWarrantsTables 39 false false R40.htm 140 - Disclosure - Stock-Based Compensation and Warrants (Details 3) Sheet http://www.entremed.com/role/StockbasedCompensationAndWarrantsDetails3 Stock-Based Compensation and Warrants (Details 3) Details http://www.entremed.com/role/StockbasedCompensationAndWarrantsTables 40 false false R41.htm 141 - Disclosure - Stock-Based Compensation and Warrants (Details Textual) Sheet http://www.entremed.com/role/StockbasedCompensationAndWarrantsDetailsTextual Stock-Based Compensation and Warrants (Details Textual) Details http://www.entremed.com/role/StockbasedCompensationAndWarrantsTables 41 false false R42.htm 142 - Disclosure - Income Taxes (Details Textual) Sheet http://www.entremed.com/role/IncomeTaxesDetailsTextual Income Taxes (Details Textual) Details http://www.entremed.com/role/IncomeTaxes 42 false false R43.htm 143 - Disclosure - Commitments (Details Textual) Sheet http://www.entremed.com/role/CommitmentsDetailsTextual Commitments (Details Textual) Details http://www.entremed.com/role/Commitments 43 false false All Reports Book All Reports casi-20180331.xml casi-20180331.xsd casi-20180331_cal.xml casi-20180331_def.xml casi-20180331_lab.xml casi-20180331_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 61 0001144204-18-028483-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-18-028483-xbrl.zip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